{"DataElement":{"publicId":"2946347","version":"1","preferredName":"Disease Present  Name","preferredDefinition":"A description of the disease present.","longName":"DZ_PRST_NM","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2013994","version":"1","preferredName":"Disease Present","preferredDefinition":"the presence of tumor or disease.","longName":"DZ_PRES","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177151","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A disease is any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function. (from Wikipedia)","longName":"Disease","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A50-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Updated to add EVS concept preferred name. dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177376","version":"1","preferredName":"Present","preferredDefinition":"Present; the period of time that is happening now.","longName":"Present","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-5263-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D06E65-88E8-7203-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2590745","version":"2","preferredName":"Disease Present Name","preferredDefinition":"The name of the subdivision of the disease found.","longName":"DZ_PRES_NM","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Absence of T and B Cells SCID","valueDescription":"Severe Combined Immunodeficiency with Absence of T and B Cells","ValueMeaning":{"publicId":"3322379","version":"1","preferredName":"Severe Combined Immunodeficiency with Absence of T and B Cells","longName":"3322379","preferredDefinition":"An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T and B cell immunity. The peripheral T and B lymphocytes are absent or in very low counts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Combined Immunodeficiency with Absence of T and B Cells","conceptCode":"C61238","definition":"An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T and B cell immunity. The peripheral T and B lymphocytes are absent or in very low counts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BACE-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BAE6-6AE7-E040-BB89AD432073","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Absence of T, Normal B Cell SCID","valueDescription":"Severe Combined Immunodeficiency with Absence of T, Normal B Cells","ValueMeaning":{"publicId":"3322380","version":"1","preferredName":"Severe Combined Immunodeficiency with Absence of T, Normal B Cells","longName":"3322380","preferredDefinition":"An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T cell immunity. The peripheral T lymphocytes are absent or in very low counts. The B lymphocyte counts are normal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Combined Immunodeficiency with Absence of T, Normal B Cells","conceptCode":"C61239","definition":"An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T cell immunity. The peripheral T lymphocytes are absent or in very low counts. The B lymphocyte counts are normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BAF0-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BB08-6AE7-E040-BB89AD432073","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acquired Pure Red Cell Aplasia","valueDescription":"Acquired Pure Red Cell Aplasia","ValueMeaning":{"publicId":"3322381","version":"1","preferredName":"Acquired Pure Red Cell Aplasia","longName":"3322381","preferredDefinition":"A disease characterized by normocytic, normochromic anemia, low hematocrit, reticulocytopenia and selective erythroid hypoplasia. It can occur as a chronic or acute form; the former is predominantly seen in adults and the latter in children.  Pathogenesis involves immune dysfunction with antibodies directed against erythroid precursor cells or erythropoietin, or due to T-cell mediated suppression of erythropoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acquired Pure Red Cell Aplasia","conceptCode":"C70548","definition":"A disease characterized by normocytic, normochromic anemia, low hematocrit, reticulocytopenia and selective erythroid hypoplasia. It can occur as a chronic or acute form; the former is predominantly seen in adults and the latter in children. Pathogenesis involves immune dysfunction with antibodies directed against erythroid precursor cells or erythropoietin, or due to T-cell mediated suppression of erythropoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB14-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BB2D-6AE7-E040-BB89AD432073","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acute Leukemia, NOS","valueDescription":"Acute Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3322382","version":"1","preferredName":"Acute Leukemia Not Otherwise Specified","longName":"3322382","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood. The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts). According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL).: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB3A-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BB53-6AE7-E040-BB89AD432073","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acute Lymphoblastic Leukemia (ALL)","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BB76-6AE7-E040-BB89AD432073","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acute Myelofibrosis or Myelosclerosis","valueDescription":"Acute Panmyelosis with Myelofibrosis","ValueMeaning":{"publicId":"2836784","version":"1","preferredName":"Acute Panmyelosis with Myelofibrosis","longName":"2836784","preferredDefinition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Panmyelosis with Myelofibrosis","conceptCode":"C4344","definition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-67F2-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BB8A-6AE7-E040-BB89AD432073","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acute Undifferentiated Leukemia","valueDescription":"Acute Undifferentiated Leukemia","ValueMeaning":{"publicId":"3322385","version":"1","preferredName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","longName":"3322385v1.00","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","conceptCode":"C82192","definition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB97-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BBB0-6AE7-E040-BB89AD432073","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Adult T-Cell Lymphoma/Leukemia","valueDescription":"Adult T-Cell Lymphoma/Leukemia","ValueMeaning":{"publicId":"2836820","version":"1","preferredName":"Adult T-Cell Lymphoma/Leukemia","longName":"2836820","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell lymphoma/leukemia is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-06CE-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BBC4-6AE7-E040-BB89AD432073","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Aggressive NK-Cell Leukemia","valueDescription":"Aggressive NK-Cell Leukemia","ValueMeaning":{"publicId":"2836819","version":"1","preferredName":"Aggressive NK-Cell Leukemia","longName":"2836819","preferredDefinition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia/lymphoma, also known as aggressive NK-cell leukemia/lymphoma, it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas.  It affects primarily teenagers and young adults.  It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.--2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive NK-Cell Leukemia","conceptCode":"C8647","definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-06AB-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BBCE-6AE7-E040-BB89AD432073","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"ALL, NOS","valueDescription":"Acute Lymphoblastic Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3322386","version":"1","preferredName":"Acute Lymphoblastic Leukemia Not Otherwise Specified","longName":"3322386","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BBDB-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BBF4-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Amegakaryocytosis (not congenital)","valueDescription":"Non-Congenital Amegakaryocytosis","ValueMeaning":{"publicId":"3322387","version":"1","preferredName":"Non-Congenital Amegakaryocytosis","longName":"3322387","preferredDefinition":"An acquired non-neoplastic disorder characterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Congenital Amegakaryocytosis","conceptCode":"C61232","definition":"An acquired non-neoplastic disorder characterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BBFE-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BC16-6AE7-E040-BB89AD432073","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Amyloidosis","valueDescription":"Amyloidosis","ValueMeaning":{"publicId":"3322390","version":"1","preferredName":"Amyloidosis","longName":"3322390","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BC68-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BC80-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Anaplastic Large-Cell Lymphoma, T / Null Cell, Primary Cutaneous Type","valueDescription":"Primary Cutaneous Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2838708","version":"1","preferredName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","longName":"2838708","preferredDefinition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","conceptCode":"C6860","definition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-971A-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BC94-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Anaplastic Large-Cell Lymphoma, T / Null Cell, Primary Systemic Type","valueDescription":"Systemic Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"3322391","version":"1","preferredName":"Systemic Anaplastic Large Cell Lymphoma","longName":"3322391","preferredDefinition":"An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Anaplastic Large Cell Lymphoma","conceptCode":"C9470","definition":"An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BC9E-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BCB6-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Angioimmunoblastic T-Cell Lymphoma","valueDescription":"Angioimmunoblastic T-Cell Lymphoma","ValueMeaning":{"publicId":"3088583","version":"1","preferredName":"Angioimmunoblastic T-Cell Lymphoma","longName":"3088583","preferredDefinition":"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites.  The clinical course is typically aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","conceptCode":"C7528","definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D15A-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BCCA-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Aspartyl Glucosaminidase","valueDescription":"Aspartylglycosaminuria","ValueMeaning":{"publicId":"3028421","version":"1","preferredName":"Aspartylglycosaminuria","longName":"3028421","preferredDefinition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartylglycosaminuria","conceptCode":"C61273","definition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD46-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BCDE-6AE7-E040-BB89AD432073","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Autoimmune Diseases","valueDescription":"Autoimmune Disease","ValueMeaning":{"publicId":"2585785","version":"1","preferredName":"Autoimmune Disease","longName":"2585785","preferredDefinition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis). \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Disease","conceptCode":"C2889","definition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26B7A966-8345-0BC2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-01-10","modifiedBy":"TAYLORT","dateModified":"2020-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BCE8-6AE7-E040-BB89AD432073","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"B-lineage, not otherwise, specified","valueDescription":"B Acute Lymphoblastic Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3322392","version":"1","preferredName":"B Acute Lymphoblastic Leukemia Not Otherwise Specified","longName":"3322392","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia. Approximately 75% of cases occur in children under six years of age. This is a good prognosis leukemia. In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%. Approximately 80% of children appear to be cured. In the adult age group the complete remission rate is 60-85%. (WHO, 2001): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BCF5-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BD0E-6AE7-E040-BB89AD432073","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Bare Lymphocyte Syndrome","valueDescription":"Bare Lymphocyte Syndrome","ValueMeaning":{"publicId":"3322393","version":"1","preferredName":"Bare Lymphocyte Syndrome","longName":"3322393","preferredDefinition":"A hereditary immunodeficiency disorder caused by the absence of major histocompatibility complex class II expression. Signs and symptoms include upper and lower respiratory tract bacterial infections, malabsorption, diarrhea, and mucocutaneous candidiasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bare Lymphocyte Syndrome","conceptCode":"C3895","definition":"A hereditary immunodeficiency disorder caused by the lack of expression of major histocompatibility complex (MHC) proteins. Signs include upper and lower respiratory tract bacterial infections, malabsorption, diarrhea, and mucocutaneous candidiasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BD18-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BD31-6AE7-E040-BB89AD432073","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Biphenotypic, Bilineage or Hybrid Leukemia","valueDescription":"Acute Leukemia of Ambiguous Lineage","ValueMeaning":{"publicId":"2835647","version":"1","preferredName":"Acute Leukemia of Ambiguous Lineage","longName":"2835647","preferredDefinition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells.  The prognosis is usually unfavorable.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia of Ambiguous Lineage","conceptCode":"C7464","definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-667C-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":"2023.3.13 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BD45-6AE7-E040-BB89AD432073","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Bone Sarcoma, Including Sarcoma PNET (excluding Ewing Sarcoma)","valueDescription":"Bone Sarcoma","ValueMeaning":{"publicId":"2593148","version":"1","preferredName":"Bone Sarcoma","longName":"2593148","preferredDefinition":"A malignant mesenchymal tumor of the bone.  Bone sarcomas can either arise from the bones (primary bone sarcomas) or spread to the bones from other anatomic sites. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Sarcoma","conceptCode":"C9312","definition":"A sarcoma that arises from the bone.  Representative examples are osteosarcoma and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E67-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BD4F-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Breast Cancer, NOS","valueDescription":"Breast Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"3232681","version":"1","preferredName":"Breast Carcinoma Not Otherwise Specified","longName":"3232681","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A24EC569-9B30-677A-E040-BB89AD433E0A","latestVersionIndicator":"Yes","beginDate":"2011-05-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BD63-6AE7-E040-BB89AD432073","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Cartilage Hair Hypoplasia","valueDescription":"Cartilage Hair Hypoplasia","ValueMeaning":{"publicId":"3322411","version":"1","preferredName":"Cartilage Hair Hypoplasia","longName":"3322411","preferredDefinition":"A rare autosomal recessive inherited disorder caused by mutation in the gene for RNAase RMRP. It is characterized by short-limb dwarfism, presence of fine sparse hair, and T-and B-cell immunodeficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cartilage Hair Hypoplasia","conceptCode":"C61245","definition":"A rare autosomal recessive inherited disorder caused by mutation in the gene for RNAase RMRP. It is characterized by short-limb dwarfism, presence of fine sparse hair, and T-and B-cell immunodeficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BDAA-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BDC2-6AE7-E040-BB89AD432073","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Chronic Myelomonocytic Leukemia (CMMoL)","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BDD6-6AE7-E040-BB89AD432073","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"CLL, B-cell / Small Cell Lymphocytic Lymphoma","valueDescription":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"2837954","version":"1","preferredName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","longName":"2837954","preferredDefinition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","conceptCode":"C27911","definition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CE74-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BDEA-6AE7-E040-BB89AD432073","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","valueDescription":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","ValueMeaning":{"publicId":"3322412","version":"1","preferredName":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","longName":"3322412","preferredDefinition":"An acute myeloid leukemia, characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines, arising de novo and not as a result of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Multilineage Dysplasia","conceptCode":"C9289","definition":"An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BE08-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36DFA8A-BE20-6AE7-E040-BB89AD432073","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Plasma Cell Leukemia","valueDescription":"Plasma Cell Leukemia","ValueMeaning":{"publicId":"3210723","version":"1","preferredName":"Plasma Cell Leukemia","longName":"3210723","preferredDefinition":"An aggressive plasma cell neoplasm with usually short survival. It is characterized by the presence of neoplastic plasma cells in the peripheral blood. The peripheral blood plasma cells comprise more than 20% of the peripheral blood white cells. It may be the initial presentation of a plasma cell neoplasm or manifest as a terminal complication of plasma cell myeloma. Lymphadenopathy and organomegaly are frequent clinical signs, whereas bone pain and osteolytic lesions are less frequently present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Leukemia","conceptCode":"C3180","definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9482-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B2E5BB-C5AD-79E2-E040-BB89AD437B0E","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Other PCD","valueDescription":"Plasma Cell Neoplasm Other","ValueMeaning":{"publicId":"3326312","version":"1","preferredName":"Plasma Cell Neoplasm Other","longName":"3326312","preferredDefinition":"An unusual leukemia characterized by the presence of clonal (malignant) plasma cells in the peripheral blood.  The plasma cells infiltrate the spleen, liver, bone marrow, and lymph nodes. The total number of leukocytes in the peripheral blood may range from normal levels to 80,000 or 90,000 per cu mm, and 5% to 90% may be plasma cells.  Although there are clinicopathologic differences between plasma cell leukemia and plasma cell myeloma, they may be phases of the same malignant process. -- 2003: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Neoplasm","conceptCode":"C4665","definition":"A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes multiple myeloma, plasma cell leukemia, plasmacytoma, and plasma cell post-transplant lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B2D4-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B2E5BB-C5A0-79E2-E040-BB89AD437B0E","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Refractory Anemia with Excess Blasts in Transformation (RAEB-t)","valueDescription":"Refractory Anemia with Excess Blasts in Transformation","ValueMeaning":{"publicId":"3338501","version":"1","preferredName":"Refractory Anemia with Excess Blasts in Transformation","longName":"3338501","preferredDefinition":"Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Anemia with Excess Blasts in Transformation","conceptCode":"C27080","definition":"Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B2E5BB-C5BA-79E2-E040-BB89AD437B0E","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B2E5BB-C5D3-79E2-E040-BB89AD437B0E","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Acquired severe aplastic anemia secondary to hepatitis","valueDescription":"Aplastic Anemia due to Hepatitis","ValueMeaning":{"publicId":"3338502","version":"1","preferredName":"Aplastic Anemia due to Hepatitis","longName":"3338502","preferredDefinition":"Bone marrow failure defined as pancytopenia, secondary to hepatitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aplastic Anemia due to Hepatitis","conceptCode":"C61231","definition":"Bone marrow failure defined as pancytopenia, secondary to hepatitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B2E5BB-C5DD-79E2-E040-BB89AD437B0E","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B2E5BB-C5F5-79E2-E040-BB89AD437B0E","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Acquired severe aplastic anemia secondary to toxin / other drug","valueDescription":"Drug-Induced Aplastic Anemia","ValueMeaning":{"publicId":"3338503","version":"1","preferredName":"Drug-Induced Aplastic Anemia","longName":"3338503","preferredDefinition":"A state of bone marrow suppression and failure that is caused by a cytotoxic or adverse immunologic response to a drug treatment, leading to a failure of production of red blood cells, white cells and platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Drug-Induced Aplastic Anemia","conceptCode":"C35343","definition":"A state of bone marrow suppression and failure that is caused by a cytotoxic or adverse immunologic response to a drug treatment, leading to a failure of production of red blood cells, white cells and platelets.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B2E5BB-C5FF-79E2-E040-BB89AD437B0E","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B2E5BB-C617-79E2-E040-BB89AD437B0E","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Small Lymphoplasmacytic Lymphoma","valueDescription":"Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"3251329","version":"1","preferredName":"Small Lymphocytic Lymphoma","longName":"3251329","preferredDefinition":"An indolent non-Hodgkin's lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Lymphocytic Lymphoma","conceptCode":"C7540","definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9BA2-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B2E5BB-C62B-79E2-E040-BB89AD437B0E","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"cALLa (includes pre-B)","valueDescription":"cALLa Positive Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3342944","version":"1","preferredName":"cALLa Positive Lymphoblastic Leukemia","longName":"3342944","preferredDefinition":"Acute lymphoblastic leukemia which is positive for the common acute lymphoblastic leukemia antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"cALLa Positive Lymphoblastic Leukemia","conceptCode":"C3165","definition":"Acute lymphoblastic leukemia which is positive for the common acute lymphoblastic leukemia antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-18BB-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-18D4-E32B-E040-BB89AD4307AD","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Classical Polyarteritis Nodosa","valueDescription":"Polyarteritis Nodosa","ValueMeaning":{"publicId":"3342945","version":"1","preferredName":"Polyarteritis Nodosa","longName":"3342945","preferredDefinition":"An autoimmune necrotizing inflammatory vasculitis that affects small and medium size arteries. It manifests with fever, fatigue, loss of appetite, weakness, skin rash, joint pain, numbness, burning sensation and renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyarteritis Nodosa","conceptCode":"C26847","definition":"A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-18DE-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-18F6-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Histiocytic Disorder, NOS","valueDescription":"Histiocytic and Dendritic Cell Neoplasm Not Otherwise Specified","ValueMeaning":{"publicId":"3342946","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasm Not Otherwise Specified","longName":"3342946","preferredDefinition":"Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1903-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-191C-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Histiocytic Disorders","valueDescription":"Histiocytic and Dendritic Cell Neoplasm","ValueMeaning":{"publicId":"3342947","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasm","longName":"3342947","preferredDefinition":"Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1926-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-193F-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Null cell (early pre-B)","valueDescription":"Pre-Pre-B Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3342948","version":"1","preferredName":"Pre-Pre-B Acute Lymphoblastic Leukemia","longName":"3342948","preferredDefinition":"Acute lymphoblastic leukemia of early B-lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pre-Pre-B Acute Lymphoblastic Leukemia","conceptCode":"C27799","definition":"Acute lymphoblastic leukemia of early B-lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-194B-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-1964-E32B-E040-BB89AD4307AD","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Other Autoimmune Bowel Disorder","valueDescription":"Inflammatory Bowel Disease Other","ValueMeaning":{"publicId":"3342949","version":"1","preferredName":"Inflammatory Bowel Disease Other","longName":"3342949","preferredDefinition":"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type. --2003: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inflammatory Bowel Disease","conceptCode":"C3138","definition":"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1971-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-198A-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Other Autoimmune Cytopenia","valueDescription":"Autoimmune Cytopenia Other","ValueMeaning":{"publicId":"3342950","version":"1","preferredName":"Autoimmune Cytopenia Other","longName":"3342950","preferredDefinition":"Cytopenia caused by autoantibodies against the red blood cells, neutrophils, and/or platelets.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Cytopenia","conceptCode":"C99382","definition":"Cytopenia caused by autoantibodies against the red blood cells, neutrophils, and/or platelets.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1997-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-19B0-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Other Autoimmune Neurological Disorder","valueDescription":"Autoimmune Nervous System Disorder Other","ValueMeaning":{"publicId":"3342951","version":"1","preferredName":"Autoimmune Nervous System Disorder Other","longName":"3342951","preferredDefinition":"A disorder characterized by the degeneration of the nervous system due to autoimmunity.  Representative examples include multiple sclerosis, Guillain-Barre syndrome, and myasthenia gravis.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Nervous System Disorder","conceptCode":"C99383","definition":"A disorder characterized by the degeneration of the nervous system due to autoimmunity.  Representative examples include multiple sclerosis, Guillain-Barre syndrome, and myasthenia gravis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-19BD-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-19D6-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Other Histiocytic Disorder","valueDescription":"Histiocytic and Dendritic Cell Neoplasm Other","ValueMeaning":{"publicId":"3342952","version":"1","preferredName":"Histiocytic and Dendritic Cell Neoplasm Other","longName":"3342952","preferredDefinition":"Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001): Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic and Dendritic Cell Neoplasm","conceptCode":"C9294","definition":"A group of rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. This category includes the following: Langerhans cell histiocytosis, Langerhans cell sarcoma, indeterminate dendritic cell histiocytosis, interdigitating dendritic cell sarcoma, histiocytic sarcoma, disseminated juvenile xanthogranuloma, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, ALK-positive histiocytosis, and follicular dendritic cell sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-19E3-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-19FC-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Other Polysaccharide Hydrolase Abnormality","valueDescription":"Polysaccharide Hydrolase Abnormality Other","ValueMeaning":{"publicId":"3342953","version":"1","preferredName":"Polysaccharide Hydrolase Abnormality Other","longName":"3342953","preferredDefinition":"An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.: A condition that differs from the usual physical or mental state.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polysaccharide Hydrolase","conceptCode":"C99387","definition":"An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Abnormality","conceptCode":"C9440","definition":"A condition that differs from the usual physical or mental state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1A0A-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-1A23-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Polysaccharide Hydrolase Abnormality, NOS","valueDescription":"Polysaccharide Hydrolase Abnormality Not Otherwise Specified","ValueMeaning":{"publicId":"3342954","version":"1","preferredName":"Polysaccharide Hydrolase Abnormality Not Otherwise Specified","longName":"3342954","preferredDefinition":"An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.: A condition that differs from the usual physical or mental state.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polysaccharide Hydrolase","conceptCode":"C99387","definition":"An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Abnormality","conceptCode":"C9440","definition":"A condition that differs from the usual physical or mental state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5B5F005-1A31-E32B-E040-BB89AD4307AD","latestVersionIndicator":"Yes","beginDate":"2012-01-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5B5F005-1A4A-E32B-E040-BB89AD4307AD","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-04","modifiedBy":"ONEDATA","dateModified":"2012-01-04","deletedIndicator":"No"},{"value":"Other Acquired Cytopenic Syndrome","valueDescription":"Aplastic Anemia Other","ValueMeaning":{"publicId":"3339731","version":"1","preferredName":"Aplastic Anemia Other","longName":"3339731","preferredDefinition":"A condition in which the bone marrow is unable to produce blood cells.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aplastic Anemia","conceptCode":"C2870","definition":"Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5183A3C-FB34-4EFE-E040-BB89AD431E29","latestVersionIndicator":"Yes","beginDate":"2011-12-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5183A3C-FB4D-4EFE-E040-BB89AD431E29","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-27","modifiedBy":"ONEDATA","dateModified":"2011-12-27","deletedIndicator":"No"},{"value":"Diamond-Blackfan Anemia (Pure Red Cell Aplasia)","valueDescription":"Diamond-Blackfan Anemia PT: Congenital Pure Red Cell Aplasia","ValueMeaning":{"publicId":"3322760","version":"1","preferredName":"Diamond-Blackfan Anemia PT: Congenital Pure Red Cell Aplasia","longName":"3322760","preferredDefinition":"An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Pure Red Cell Aplasia","conceptCode":"C61236","definition":"An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A77C-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A795-7A8F-E040-BB89AD43536C","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Diffuse, Large B-cell Lymphoma, Including Primary Mediastinal (thymic) Large B-cell Lymphoma (large B-cell subtype)","valueDescription":"Mediastinal (Thymic) Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838609","version":"1","preferredName":"Mediastinal (Thymic) Large B-Cell Lymphoma","longName":"2838609","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AEF5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A7A9-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Enteropathy-type T-Cell Lymphoma","valueDescription":"Enteropathy-Associated T-Cell Lymphoma","ValueMeaning":{"publicId":"3322761","version":"1","preferredName":"Enteropathy-Associated T-Cell Lymphoma","longName":"3322761","preferredDefinition":"An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enteropathy-Associated T-Cell Lymphoma","conceptCode":"C4737","definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A7B3-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A7CC-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Essential or Primary Thrombocythemia","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A7E0-7A8F-E040-BB89AD43536C","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Evan Syndrome","valueDescription":"Evans Syndrome","ValueMeaning":{"publicId":"3322762","version":"1","preferredName":"Evans Syndrome","longName":"3322762","preferredDefinition":"A rare, chronic and relapsing autoimmune disorder of unknown etiology, characterized by the presence of immune thrombocytopenia and autoimmune hemolytic anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Evans Syndrome","conceptCode":"C61284","definition":"A rare, chronic and relapsing autoimmune disorder of unknown etiology, characterized by the presence of immune thrombocytopenia and autoimmune hemolytic anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A7EA-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A803-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type","valueDescription":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","ValueMeaning":{"publicId":"3322763","version":"1","preferredName":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"3322763","preferredDefinition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells). The gastrointestinal tract is the most common site of involvement. Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast. Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A80D-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A825-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Familial Erythrohemophagocytic Lymphohistiocytosis (FELH)","valueDescription":"Familiar Hemophagocytic Lymphohistiocytosis","ValueMeaning":{"publicId":"3322764","version":"1","preferredName":"Familiar Hemophagocytic Lymphohistiocytosis","longName":"3322764","preferredDefinition":"A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Hemophagocytic Lymphohistiocytosis","conceptCode":"C61276","definition":"A rare, life-threatening disorder usually appearing during the first few months of life. It is caused by abnormalities in the PRF1, UNC13D, and STX11 genes. It is characterized by histiocytic proliferation and phagocytosis. Patients present with fever, lymphadenopathy, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A82F-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A847-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Follicular (grade unknown)","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A85B-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Follicular, Mixed, Small Cleaved and Large Cell (Grade II Follicle Center Lymphoma)","valueDescription":"Grade 2 Follicular Lymphoma","ValueMeaning":{"publicId":"3088717","version":"1","preferredName":"Grade 2 Follicular Lymphoma","longName":"3088717","preferredDefinition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2 Follicular Lymphoma","conceptCode":"C8968","definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E480BB-B6CD-7B51-E040-BB89AD433123","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A86F-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Follicular, Predominantly Large Cell (Grade III Follicle Center Lymphoma)","valueDescription":"Grade 3 Follicular Lymphoma","ValueMeaning":{"publicId":"2593084","version":"1","preferredName":"Grade 3 Follicular Lymphoma","longName":"2593084","preferredDefinition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3 Follicular Lymphoma","conceptCode":"C3460","definition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A89-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A879-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Fucosidosis","valueDescription":"Fucosidosis","ValueMeaning":{"publicId":"3028419","version":"1","preferredName":"Fucosidosis","longName":"3028419","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fucosidosis","conceptCode":"C61274","definition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCFE-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A883-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Gaucher Disease","valueDescription":"Gaucher Disease","ValueMeaning":{"publicId":"3028418","version":"1","preferredName":"Gaucher Disease","longName":"3028418","preferredDefinition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gaucher Disease","conceptCode":"C61268","definition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCDB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A88D-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Germ Cell Tumor, Extragonadal","valueDescription":"Extragonadal Germ Cell Tumor","ValueMeaning":{"publicId":"3322765","version":"1","preferredName":"Extragonadal Germ Cell Tumor","longName":"3322765","preferredDefinition":"A germ cell tumor arising in an anatomic site other than the testis or ovary (e.g., central nervous system, lung, mediastinum, and retroperitoneum).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extragonadal Germ Cell Tumor","conceptCode":"C3918","definition":"A germ cell tumor arising in an anatomic site other than the testis or ovary (e.g., central nervous system, lung, mediastinum, and retroperitoneum).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A897-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A8AF-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hepatobiliary","valueDescription":"Hepato-Biliary Neoplasm","ValueMeaning":{"publicId":"3322766","version":"1","preferredName":"Hepato-Biliary Neoplasm","longName":"3322766","preferredDefinition":"A benign or malignant neoplasm involving the liver or the biliary tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatobiliary Neoplasm","conceptCode":"C8614","definition":"A benign or malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples of benign neoplasms include hepatocellular adenoma, bile duct adenoma, and gallbladder lipoma.  Representative examples of malignant neoplasms include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A8B9-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A8D1-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hepatosplenic gamma-delta T-cell Lymphoma","valueDescription":"Hepatosplenic T-Cell Lymphoma","ValueMeaning":{"publicId":"2838581","version":"1","preferredName":"Hepatosplenic T-Cell Lymphoma","longName":"2838581","preferredDefinition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatosplenic T-Cell Lymphoma","conceptCode":"C8459","definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-58F8-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A8E5-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"High Grade B-cell Lymphoma, Burkitt-Like (provisional entity)","valueDescription":"Atypical Burkitt/Burkitt-Like Lymphoma","ValueMeaning":{"publicId":"3322767","version":"1","preferredName":"Atypical Burkitt/Burkitt-Like Lymphoma","longName":"3322767","preferredDefinition":"A morphologic variant of Burkitt lymphoma characterized by marked nuclear pleomorphism, abundant apoptotic debris, and the presence of tangible body macrophages.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Burkitt/Burkitt-Like Lymphoma","conceptCode":"C6917","definition":"A morphologic variant of Burkitt lymphoma characterized by marked nuclear pleomorphism, abundant apoptotic debris, and the presence of tangible body macrophages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A8EF-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A907-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hodgkin Lymphoma, NOS","valueDescription":"Hodgkin Lymphoma Not Otherwise Specified","ValueMeaning":{"publicId":"3322768","version":"1","preferredName":"Hodgkin Lymphoma Not Otherwise Specified","longName":"3322768","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A914-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A92D-7A8F-E040-BB89AD43536C","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hunter Syndrome","valueDescription":"Hunter Syndrome","ValueMeaning":{"publicId":"3322769","version":"1","preferredName":"Hunter Syndrome","longName":"3322769","preferredDefinition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides. It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hunter Syndrome","conceptCode":"C61260","definition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A937-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A950-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hurler Syndrome","valueDescription":"Hurler Syndrome","ValueMeaning":{"publicId":"3028416","version":"1","preferredName":"Hurler Syndrome","longName":"3028416","preferredDefinition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hurler Syndrome","conceptCode":"C61261","definition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC95-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A95A-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"I-Cell Disease","valueDescription":"I-Cell Disease","ValueMeaning":{"publicId":"3188499","version":"1","preferredName":"I-Cell Disease","longName":"3188499","preferredDefinition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"I-Cell Disease","conceptCode":"C61270","definition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B6858FA-72BE-8EA3-E040-BB89AD433118","latestVersionIndicator":"Yes","beginDate":"2011-02-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A96E-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Inherited Abnormalities of Platelets","valueDescription":"Congenital Platelets Abnormality","ValueMeaning":{"publicId":"3115733","version":"1","preferredName":"Congenital Platelets Abnormality","longName":"3115733","preferredDefinition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Platelets Abnormality","conceptCode":"C61247","definition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A436A18-387F-2C9C-E040-BB89AD43650B","latestVersionIndicator":"Yes","beginDate":"2010-06-30","endDate":null,"createdBy":"WHITES","dateCreated":"2010-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A982-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Inherited Abnormalities of Erythrocyte Differentiation or Function, NOS","valueDescription":"Congenital Abnormalities of Erythrocyte Differentiation or Function Not Otherwise Specified","ValueMeaning":{"publicId":"3322770","version":"1","preferredName":"Congenital Abnormalities of Erythrocyte Differentiation or Function Not Otherwise Specified","longName":"3322770","preferredDefinition":"Inherited disorders involving abnormalities of red blood cell function, structure, or production.  Some diseases in this group may be associated with bone marrow failure, neutropenia, and/or thrombocytopenia.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Abnormalities of Erythrocyte Differentiation or Function","conceptCode":"C61234","definition":"Inherited disorders involving abnormalities of red blood cell function, structure, or production. Some diseases in this group may be associated with bone marrow failure, neutropenia, and/or thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A98F-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A9A8-7A8F-E040-BB89AD43536C","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Inherited Disorders of Metabolism","valueDescription":"Congenital Metabolic Disorder","ValueMeaning":{"publicId":"2593446","version":"1","preferredName":"Congenital Metabolic Disorder","longName":"2593446","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAAEC-6B31-4B12-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A9B2-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Inherited Metabolic Disorder, NOS","valueDescription":"Congenital Metabolic Disorder Not Otherwise Specified","ValueMeaning":{"publicId":"3322771","version":"1","preferredName":"Congenital Metabolic Disorder Not Otherwise Specified","longName":"3322771","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A9BF-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A9D8-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Inherited Platelet Abnormality, NOS","valueDescription":"Congenital Platelets Abnormality Not Otherwise Specified","ValueMeaning":{"publicId":"3322772","version":"1","preferredName":"Congenital Platelets Abnormality Not Otherwise Specified","longName":"3322772","preferredDefinition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Platelets Abnormality","conceptCode":"C61247","definition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A9E5-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-A9FE-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Intestinal Disorder","valueDescription":"Intestinal Disorder","ValueMeaning":{"publicId":"3322773","version":"1","preferredName":"Intestinal Disorder","longName":"3322773","preferredDefinition":"Any disease of the small or large intestine.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intestinal Disorder","conceptCode":"C26801","definition":"A non-neoplastic or neoplastic disorder that affects the small or large intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-AA08-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3714D57-AA20-7A8F-E040-BB89AD43536C","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acute Myelogenous Leukemia","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A655-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M3, promyelocytic (APML, APL)","valueDescription":"APL","ValueMeaning":{"publicId":"2590750","version":"1","preferredName":"APL","longName":"2590750","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and micro granular (hypo granular) variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-041A-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A687-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M7, megakaryoblastic","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2558163","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2558163","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B040-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A6AF-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"T-cell","valueDescription":"Precursor T-Lymphoblastic Leukemia","ValueMeaning":{"publicId":"2590758","version":"1","preferredName":"Precursor T-Lymphoblastic Leukemia","longName":"2590758","preferredDefinition":"This type of acute lymphoblastic leukemia comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-0505-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A6EB-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Large T-cell granular lymphocytic leukemia","valueDescription":"T-Cell Large Granular Lymphocyte Leukemia","ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A6FF-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Acute Mast Cell Leukemia","valueDescription":"Mast Cell Leukemia","ValueMeaning":{"publicId":"2590857","version":"1","preferredName":"Mast Cell Leukemia","longName":"2590857","preferredDefinition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Leukemia","conceptCode":"C3169","definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B55A-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A731-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Chronic Myelogenous Leukemia (CML)","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"2558495","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"2558495","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B18C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A745-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hairy Cell Leukemia","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2558848","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2558848","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B2ED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A7D1-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Myelodysplastic (MDS) / Myeloproliferative (MPS) Disorders","valueDescription":"Myelodysplastic/Myeloproliferative Disease","ValueMeaning":{"publicId":"2590868","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Disease","longName":"2590868","preferredDefinition":"A category of clonal myeloid disorders that have both myelodysplastic and chronic myeloproliferative features at the time of initial presentation.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm","conceptCode":"C27262","definition":"A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"284500E6-BC71-45B5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A80D-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Polycythemia Vera","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2559822","version":"1","preferredName":"Polycythemia Vera","longName":"2559822","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A85D-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Juvenile CML (JMML or JCML) (no evidence of Ph1 or BCR/ABL)","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2559013","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2559013","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B392-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A885-9DF5-E040-BB89AD4316B4","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Solitary Plasmacytoma","valueDescription":"Solitary Plasmacytoma","ValueMeaning":{"publicId":"2579743","version":"1","preferredName":"Solitary Plasmacytoma","longName":"2579743","preferredDefinition":"A localized clonal (malignant) plasma cell infiltrate either in the bone or in another anatomic site without peripheral blood involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Plasmacytoma","conceptCode":"C6932","definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-048C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A8A3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Non-Hodgkin's Lymphoma","valueDescription":"Non-Hodgkin lymphoma","ValueMeaning":{"publicId":"2568326","version":"1","preferredName":"Non-Hodgkin lymphoma","longName":"2568326","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-02","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A8C1-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Splenic Marginal Zone B-Cell Lymphoma","valueDescription":"splenic marginal zone B-cell lymphoma","ValueMeaning":{"publicId":"2579748","version":"1","preferredName":"splenic marginal zone B-cell lymphoma","longName":"2579748","preferredDefinition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  The patients present with splenomegaly and the clinical course is indolent.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Marginal Zone Lymphoma","conceptCode":"C4663","definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0491-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A8DF-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Follicular, Predominantly Small Cleaved Cell (Grade I Follicle Center Lymphoma)","valueDescription":"Grade 1 Follicular Lymphoma","ValueMeaning":{"publicId":"2593080","version":"1","preferredName":"Grade 1 Follicular Lymphoma","longName":"2593080","preferredDefinition":"A low-grade malignant lymphoma of predominantly follicular pattern. Follicles are of relatively uniform size and shape and the cells are usually somewhat larger than normal lymphocytes. Nuclei are irregular with prominent indentations and cytoplasm can rarely be identified. Cells exhibiting these characteristics are often called small cleaved cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1 Follicular Lymphoma","conceptCode":"C3465","definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A3B-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A8F3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Burkitt Lymphoma / Burkitt Cell Leukemia","valueDescription":"Burkitt Lymphoma","ValueMeaning":{"publicId":"2568284","version":"1","preferredName":"Burkitt Lymphoma","longName":"2568284","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt's lymphoma, Burkitt's lymphoma with plasmacytoid differentiation, and atypical Burkitt's/Burkitt's-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":"04/13/2011 - tc - Updated with current NCIt name and definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A957-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Extranodal NK / T-cell Lymphoma, Nasal Type","valueDescription":"Nasal Type Extranodal NK/T-Cell Lymphoma","ValueMeaning":{"publicId":"2593089","version":"1","preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","longName":"2593089","preferredDefinition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma.  It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells.  The nasal cavity is the commonest site of involvement.  Patients often present with midfacial destructive lesions (lethal midline granuloma).  The disease may disseminate rapidly to various anatomic sites including gastrointestinal tract, skin, testis, and cervical lymph nodes.  It is also known as angiocentric T-cell lymphoma.  The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma.  However, the latter term may also apply to lymphomatoid granulomatosis which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Type Extranodal NK/T-Cell Lymphoma","conceptCode":"C4684","definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8F3E-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A975-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Subcutaneous Panniculitis-Like T-cell Lymphoma","valueDescription":"Subcutaneous Panniculitis-Like T-Cell ","ValueMeaning":{"publicId":"2560116","version":"1","preferredName":"Subcutaneous Panniculitis-Like T-Cell ","longName":"2560116","preferredDefinition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","conceptCode":"C6918","definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A993-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Primary CNS Lymphoma","valueDescription":"Central Nervous System Lymphoma","ValueMeaning":{"publicId":"2573501","version":"1","preferredName":"Central Nervous System Lymphoma","longName":"2573501","preferredDefinition":"Cancer that arises in the lymphoid tissue found in the central nervous system (CNS). The CNS includes the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Lymphoma","conceptCode":"C9301","definition":"A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A9CF-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hodgkin Lymphoma","valueDescription":"Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2581278","version":"1","preferredName":"Hodgkin's Lymphoma","longName":"2581278","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.  Hodgkin's lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin's lymphoma has resulted in an excellent outcome and cure for the majority of patients. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A9E3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lymphocyte-Rich","valueDescription":"Lymphocyte Rich Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593110","version":"1","preferredName":"Lymphocyte Rich Classical Hodgkin Lymphoma","longName":"2593110","preferredDefinition":"A subtype of classical Hodgkin lymphoma.  Most patients present with peripheral lymphadenopathy and limited stage disease (stage I or II).  The survival and progression free survival are slightly better than in other subtypes of classical Hodgkin lymphoma. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","conceptCode":"C6913","definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C748-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A9ED-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Nodular Sclerosis","valueDescription":"Nodular Sclerosis Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593112","version":"1","preferredName":"Nodular Sclerosis Hodgkin Lymphoma","longName":"2593112","preferredDefinition":"A subtype of classical Hodgkin lymphoma characterized by collagen bands surrounding lymphoid nodules. The lymphoid nodules contain lacunar and Reed-Sternberg cells.  Mediastinal involvement occurs in 80% of patients.  The prognosis of nodular sclerosis Hodgkin lymphoma is slightly better than that of mixed cellularity or lymphocyte depleted subtype. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Sclerosis Classic Hodgkin Lymphoma","conceptCode":"C3518","definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C76F-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-A9F7-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lymphocyte Depleted","valueDescription":"Lymphocyte Depleted Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593114","version":"1","preferredName":"Lymphocyte Depleted Hodgkin Lymphoma","longName":"2593114","preferredDefinition":"A diffuse form of classical Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes.  Historically, the clinical course of this type of Hodgkin lymphoma was aggressive.  With current therapy, the course is comparable to patients with other subtypes of classical Hodgkin lymphoma.  Most patients present with advanced stage disease (Stage III or IV) and B-symptoms. (WHO, 2001) -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","conceptCode":"C9283","definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C796-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA01-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mixed Cellularity","valueDescription":"Mixed Cellularity Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593119","version":"1","preferredName":"Mixed Cellularity Hodgkin Lymphoma","longName":"2593119","preferredDefinition":"A subtype of classical Hodgkin lymphoma with a mixed inflammatory stroma containing Hodgkin and Reed-Sternberg cells.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Cellularity Classic Hodgkin Lymphoma","conceptCode":"C3517","definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4CEB-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added Manually curated definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA0B-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Solid Tumor","valueDescription":"Solid Neoplasm","ValueMeaning":{"publicId":"2593121","version":"1","preferredName":"Solid Neoplasm","longName":"2593121","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4D12-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA15-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Inflammatory Breast Carcinoma","valueDescription":"Inflammatory Breast Carcinoma","ValueMeaning":{"publicId":"2593123","version":"1","preferredName":"Inflammatory Breast Carcinoma","longName":"2593123","preferredDefinition":"A type of breast cancer in which the breast looks red and swollen and feels warm. The skin of the breast may also show the pitted appearance called peau d'orange (like the skin of an orange). The redness and warmth occur because the cancer cells block the lymph vessels in the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Inflammatory Carcinoma","conceptCode":"C4001","definition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4D39-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA1F-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lung, Small Cell","valueDescription":"SCLC","ValueMeaning":{"publicId":"2593141","version":"1","preferredName":"SCLC","longName":"2593141","preferredDefinition":"A type of lung cancer in which the cells appear small and round when viewed under the microscope. Also called oat cell lung cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Small Cell Carcinoma","conceptCode":"C4917","definition":"A highly aggressive carcinoma with neuroendocrine differentiation arising from the lung. It is characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6DAC-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA3D-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lung, Non-Small Cell","valueDescription":"Non-Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"2581628","version":"1","preferredName":"Non-Small Cell Lung Carcinoma","longName":"2581628","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA47-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Ewing Sarcoma","valueDescription":"Ewing Sarcoma","ValueMeaning":{"publicId":"2593150","version":"1","preferredName":"Ewing Sarcoma","longName":"2593150","preferredDefinition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma","conceptCode":"C4817","definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E8E-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA83-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Fibrosarcoma","valueDescription":"Fibrosarcoma","ValueMeaning":{"publicId":"2568825","version":"1","preferredName":"Fibrosarcoma","longName":"2568825","preferredDefinition":"A malignant mesenchymal tumor affecting soft tissues and bone. It is classified as adult or infantile.  Infantile fibrosarcomas generally have a much more favorable prognosis than adult fibrosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrosarcoma","conceptCode":"C3043","definition":"A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9E6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA8D-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hemangiosarcoma","valueDescription":"Angiosarcoma","ValueMeaning":{"publicId":"2568840","version":"1","preferredName":"Angiosarcoma","longName":"2568840","preferredDefinition":"A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Angiosarcoma","conceptCode":"C3088","definition":"A malignant tumor arising from the endothelial cells of the blood vessels.  Microscopically, it is characterized by frequently open vascular anastomosing and branching channels.  The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei.  Angiosarcomas most frequently occur in the skin and breast.  Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9F5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AA97-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Leiomyosarcoma","valueDescription":"Leiomyosarcoma","ValueMeaning":{"publicId":"2562491","version":"1","preferredName":"Leiomyosarcoma","longName":"2562491","preferredDefinition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyosarcoma","conceptCode":"C3158","definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C128-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-09-27","endDate":null,"createdBy":"PWEST","dateCreated":"2002-09-27","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAA1-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Liposarcoma","valueDescription":"Liposarcoma","ValueMeaning":{"publicId":"2579805","version":"1","preferredName":"Liposarcoma","longName":"2579805","preferredDefinition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposarcoma","conceptCode":"C3194","definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAAB-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lymphangiosarcoma","valueDescription":"Lymphangiosarcoma","ValueMeaning":{"publicId":"2593155","version":"1","preferredName":"Lymphangiosarcoma","longName":"2593155","preferredDefinition":"A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphangiosarcoma","conceptCode":"C3205","definition":"A malignant neoplasm arising from the endothelial cells of the lymphatic vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6EFF-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAB5-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Neurogenic Sarcoma","valueDescription":"Peripheral Primitive Neuroectodermal Tumor","ValueMeaning":{"publicId":"2593157","version":"1","preferredName":"Peripheral Primitive Neuroectodermal Tumor","longName":"2593157","preferredDefinition":"A group of highly cellular primitive round cell neoplasms which occur extracranially in soft tissue and bone and are derived from embryonal neural crest cells. These tumors occur primarily in children and adolescents and share a number of characteristics with Ewing's Sarcoma (SARCOMA, EWING'S). They may arise from the chest wall, skin, orbit, kidney, and other structures and tend to be locally invasive or metastasize, although relatively benign forms may occur. Characteristic histologic features include a tendency to form Homer-Wright rosettes and to stain positively with neuron-specific enolase and vimentin. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2113; J Clin Oncol 1998 Mar;16(3):1150-7)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Primitive Neuroectodermal Tumor","conceptCode":"C9341","definition":"A small round cell tumor with neural differentiation arising from the soft tissues or bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6F26-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AABF-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Rhabdomyosarcoma","valueDescription":"Stratum 4: Rhabdomyosarcoma","ValueMeaning":{"publicId":"2574678","version":"1","preferredName":"Stratum 4: Rhabdomyosarcoma","longName":"2574678","preferredDefinition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults.  Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdomyosarcoma","conceptCode":"C3359","definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F0C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-01","modifiedBy":"CAMPBELB","dateModified":"2013-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAC9-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Synovial Sarcoma","valueDescription":"Synovial sarcoma","ValueMeaning":{"publicId":"2568843","version":"1","preferredName":"Synovial sarcoma","longName":"2568843","preferredDefinition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Synovial Sarcoma","conceptCode":"C3400","definition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9F8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAD3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"JIA: Oligoarticular","valueDescription":"Oligoarticular Still Disease","ValueMeaning":{"publicId":"3323197","version":"1","preferredName":"Oligoarticular Still Disease","longName":"3323197","preferredDefinition":"Juvenile rheumatoid arthritis affecting four or fewer joints, usually asymmetrically. The most commonly affected joints are the knee, elbow, wrist, and ankle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligoarticular Still Disease","conceptCode":"C61279","definition":"Juvenile rheumatoid arthritis affecting four or fewer joints, usually asymmetrically. The most commonly affected joints are the knee, elbow, wrist, and ankle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AEF8-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AF11-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"JIA: Polyarticular","valueDescription":"Polyarticular Still Disease","ValueMeaning":{"publicId":"3323198","version":"1","preferredName":"Polyarticular Still Disease","longName":"3323198","preferredDefinition":"Juvenile rheumatoid arthritis affecting multiple joints, usually symmetrically. It may be associated with low grade fever, anemia, and weight loss. Patients usually test negative for rheumatoid factor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyarticular Still Disease","conceptCode":"C61280","definition":"Juvenile rheumatoid arthritis affecting multiple joints, usually symmetrically. It may be associated with low grade fever, anemia, and weight loss. Patients usually test negative for rheumatoid factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AF1B-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AF34-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Kostmann Agranulocytosis (Congenital Neutropenia)","valueDescription":"Congenital Neutropenia","ValueMeaning":{"publicId":"3323199","version":"1","preferredName":"Congenital Neutropenia","longName":"3323199","preferredDefinition":"A rare disorder characterized by recurrent infantile infections and absence of neutrophils in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Neutropenia","conceptCode":"C61242","definition":"A rare congenital disorder characterized by mild or severe reduction of neutrophils in the peripheral blood and recurrent infantile infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AF3E-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AF56-5E8E-E040-BB89AD433884","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lesch-Nyhan (HGPRT Deficiency)","valueDescription":"Lesch-Nyhan Syndrome","ValueMeaning":{"publicId":"3028414","version":"1","preferredName":"Lesch-Nyhan Syndrome","longName":"3028414","preferredDefinition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesch-Nyhan Syndrome","conceptCode":"C61255","definition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC4F-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AF6A-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Leukemia, NOS","valueDescription":"Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3323200","version":"1","preferredName":"Leukemia Not Otherwise Specified","longName":"3323200","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AF77-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AF90-5E8E-E040-BB89AD433884","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Leukocyte Adhesion Deficiencies, including GP180, CD-18, LFA and WBC Adhesion Defic","valueDescription":"Leukocyte Adhesion Deficiency","ValueMeaning":{"publicId":"3323201","version":"1","preferredName":"Leukocyte Adhesion Deficiency","longName":"3323201","preferredDefinition":"A rare autosomal recessive immunodeficiency disorder caused by deficiency of CD18 expression. It is characterized by defects in neutrophil adhesion and bacterial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukocyte Adhesion Deficiency","conceptCode":"C27874","definition":"A rare autosomal recessive immunodeficiency disorder caused by deficiency of CD18 expression. It is characterized by defects in neutrophil adhesion and bacterial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AF9A-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AFB2-5E8E-E040-BB89AD433884","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lung, NOS","valueDescription":"Lung Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"3323202","version":"1","preferredName":"Lung Carcinoma Not Otherwise Specified","longName":"3323202","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AFBF-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AFD8-5E8E-E040-BB89AD433884","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Lysosomal Storage Disease","valueDescription":"Lysosomal Storage Disease","ValueMeaning":{"publicId":"3251364","version":"1","preferredName":"Lysosomal Storage Disease","longName":"3251364","preferredDefinition":"A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes.  Signs and symtoms include hepatomegaly, splenomegaly, nervous sytem manifestations, skeletal abnormalities, and mental deterioration.  Representative examples, include Gaucher disease, Neimann-Pick disease, Wolman disease, and Fabry disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lysosomal Storage Disease","conceptCode":"C61250","definition":"A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes. Signs and symptoms include hepatomegaly, splenomegaly, nervous system manifestations, skeletal abnormalities, and mental deterioration. Representative examples include Gaucher disease, Niemann-Pick disease, Wolman disease, and Fabry disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-A15A-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-AFEC-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M0, stem cell","valueDescription":"Acute Myeloid Leukemia, Minimally Differentiated","ValueMeaning":{"publicId":"3323203","version":"1","preferredName":"Acute Myeloid Leukemia, Minimally Differentiated","longName":"3323203","preferredDefinition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Minimal Differentiation","conceptCode":"C8460","definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-AFF6-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B00E-5E8E-E040-BB89AD433884","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M1, myeloblastic","valueDescription":"Acute Myeloid Leukemia without Maturation","ValueMeaning":{"publicId":"2836808","version":"1","preferredName":"Acute Myeloid Leukemia without Maturation","longName":"2836808","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia without Maturation","conceptCode":"C3249","definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A96F-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B022-5E8E-E040-BB89AD433884","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M2, myelocytic","valueDescription":"Acute Myeloid Leukemia with Maturation","ValueMeaning":{"publicId":"2836809","version":"1","preferredName":"Acute Myeloid Leukemia with Maturation","longName":"2836809","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A992-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B036-5E8E-E040-BB89AD433884","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M4, myelomonocytic (AMML)","valueDescription":"Acute Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2836785","version":"1","preferredName":"Acute Myelomonocytic Leukemia","longName":"2836785","preferredDefinition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia","conceptCode":"C7463","definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6815-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B04A-5E8E-E040-BB89AD433884","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M5, monocytic (AMMOL)","valueDescription":"Acute Monocytic Leukemia","ValueMeaning":{"publicId":"2590752","version":"1","preferredName":"Acute Monocytic Leukemia","longName":"2590752","preferredDefinition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monocytic Leukemia","conceptCode":"C4861","definition":"An acute myeloid leukemia in which the majority of monocytic cells are promonocytes.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-0456-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B05E-5E8E-E040-BB89AD433884","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"M6, erythroblastic (AEL)","valueDescription":"Acute Erythroid Leukemia","ValueMeaning":{"publicId":"2836778","version":"1","preferredName":"Acute Erythroid Leukemia","longName":"2836778","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-675B-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B072-5E8E-E040-BB89AD433884","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mannosidosis","valueDescription":"Mannosidosis","ValueMeaning":{"publicId":"3323204","version":"1","preferredName":"Mannosidosis","longName":"3323204","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase.  Clincal signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mannosidosis","conceptCode":"C61275","definition":"A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase. Clinical signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B07C-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B095-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mantle Cell Lymphoma","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B09F-5E8E-E040-BB89AD433884","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Maroteaux-Lamy (VI)","valueDescription":"Maroteaux-Lamy Syndrome","ValueMeaning":{"publicId":"3028412","version":"1","preferredName":"Maroteaux-Lamy Syndrome","longName":"3028412","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maroteaux-Lamy Syndrome","conceptCode":"C61264","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC07-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B0B3-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"MDS Disorder, NOS","valueDescription":"Myelodysplastic Syndrome Not Otherwise Specified","ValueMeaning":{"publicId":"3323205","version":"1","preferredName":"Myelodysplastic Syndrome Not Otherwise Specified","longName":"3323205","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B0C0-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B0D9-5E8E-E040-BB89AD433884","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"MPS Disorder, NOS","valueDescription":"Myeloproliferative Neoplasm Not Otherwise Specified","ValueMeaning":{"publicId":"3323206","version":"1","preferredName":"Myeloproliferative Neoplasm Not Otherwise Specified","longName":"3323206","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B0E6-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B0FF-5E8E-E040-BB89AD433884","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Central Nervous System Tumor, Including CNS PNET","valueDescription":"Central Nervous System Neoplasm","ValueMeaning":{"publicId":"2593161","version":"1","preferredName":"Central Nervous System Neoplasm","longName":"2593161","preferredDefinition":"Abnormal growth of cells that comprise the tissues of the central nervous system (brain and spinal cord), without designation of benign or malignant nature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Neoplasm","conceptCode":"C9293","definition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6FA9-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAF1-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Medulloblastoma","valueDescription":"Medulloblastoma","ValueMeaning":{"publicId":"2578699","version":"1","preferredName":"Medulloblastoma","longName":"2578699","preferredDefinition":"A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0078-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AAFB-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Neuroblastoma","valueDescription":"Neuroblastoma","ValueMeaning":{"publicId":"2573075","version":"1","preferredName":"Neuroblastoma","longName":"2573075","preferredDefinition":"Neuroblastoma is a specific type of neuroblastic tumor which is characterized by the presense of neuroblastic cells forming groups or nests separated by delicate stromal septa without prominent Schwannian stroma. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA80-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AB05-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mediastinal Neoplasm","valueDescription":"Mediastinal Neoplasm","ValueMeaning":{"publicId":"2593231","version":"1","preferredName":"Mediastinal Neoplasm","longName":"2593231","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm affecting the mediastinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mediastinal Neoplasm","conceptCode":"C3221","definition":"A benign or malignant neoplasm that affects the structures of the mediastinum.  Representative examples include mediastinal lipoma, mediastinal schwannoma, thymoma, mediastinal germ cell tumor, and mediastinal lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2870B392-3B41-4CD9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AB0F-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","valueDescription":"Paroxysmal Nocturnal Hemoglobinuria","ValueMeaning":{"publicId":"2593267","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria","longName":"2593267","preferredDefinition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxysmal Nocturnal Hemoglobinuria","conceptCode":"C61233","definition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880CCB0-13F1-07E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AB9B-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Fanconi Anemia","valueDescription":"Fanconi anemia","ValueMeaning":{"publicId":"2579909","version":"1","preferredName":"Fanconi anemia","longName":"2579909","preferredDefinition":"A rare and often fatal inherited disease in which the bone marrow fails to produce red blood cells, white blood cells, platelets, or a combination of these cells. The disease may transform into myelodysplastic syndrome or leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0532-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ABD7-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Sickle Cell Disease","valueDescription":"sickle cell disease","ValueMeaning":{"publicId":"2579911","version":"1","preferredName":"sickle cell disease","longName":"2579911","preferredDefinition":"A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sickle Cell Disease","conceptCode":"C34383","definition":"A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0534-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ABEB-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Thalassemia","valueDescription":"Thalassemia","ValueMeaning":{"publicId":"2593293","version":"1","preferredName":"Thalassemia","longName":"2593293","preferredDefinition":"A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalassemia","conceptCode":"C35069","definition":"An inherited blood disorder characterized by a decreased synthesis of one of the polypeptide chains that form hemoglobin. Anemia results from this abnormal hemoglobin formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28821A33-CC97-19A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ABF5-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Disorders of the Immune System","valueDescription":"Immune System Disorder","ValueMeaning":{"publicId":"2578546","version":"1","preferredName":"Immune System Disorder","longName":"2578546","preferredDefinition":"A disorder resulting from an abnormality in the immune system. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune System Disorder","conceptCode":"C3507","definition":"A disorder resulting from an abnormality in the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFDF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"ONEDATA","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC13-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Adenosine Deaminase (ADA) Deficiency / Severe Combined Immunodefiency (SCID)","valueDescription":"Adenosine Deaminase Deficiency","ValueMeaning":{"publicId":"2593377","version":"1","preferredName":"Adenosine Deaminase Deficiency","longName":"2593377","preferredDefinition":"An autosomal recessive deficiency of the purine salvage enzyme adenosine deaminase which results in Severe Combined Immunodeficiency Disease (SCID).  The most common form of SCID, accounting for about 50% of autosomal recessive cases.  The first disease for which gene therapy was applied.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosine Deaminase Deficiency","conceptCode":"C3962","definition":"An autosomal recessive deficiency of the purine salvage enzyme adenosine deaminase which results in Severe Combined Immunodeficiency Disease (SCID).  The most common form of SCID, accounting for about 50% of autosomal recessive cases.  The first disease for which gene therapy was applied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2883B38F-10CD-4337-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC1D-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Head /  Neck","valueDescription":"Head and Neck Neoplasm","ValueMeaning":{"publicId":"2593169","version":"1","preferredName":"Head and Neck Neoplasm","longName":"2593169","preferredDefinition":"A benign or malignant neoplasm affecting one of the following areas: base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Neoplasm","conceptCode":"C3077","definition":"A benign or malignant neoplasm that affects the anatomic structures of the head and neck region.  Representative examples of benign neoplasms include salivary gland pleomorphic adenoma and nasal cavity papilloma.  Representative examples of malignant neoplasms include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6596-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC31-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Gastric","valueDescription":"Gastric Neoplasm","ValueMeaning":{"publicId":"2593172","version":"1","preferredName":"Gastric Neoplasm","longName":"2593172","preferredDefinition":"Cancerous or non-cancerous tumors of the stomach","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Neoplasm","conceptCode":"C3387","definition":"A benign or malignant neoplasm involving the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-65CB-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC3B-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Pancreatic","valueDescription":"Pancreatic Neoplasm","ValueMeaning":{"publicId":"2593173","version":"1","preferredName":"Pancreatic Neoplasm","longName":"2593173","preferredDefinition":"Abnormal growth of the cells (either cancerous or non-cancerous) of the pancreas, the gland that secrets insulin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neoplasm","conceptCode":"C3305","definition":"A benign or malignant neoplasm involving the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-65E5-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC45-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mucolipidosis","valueDescription":"Mucolipidosis","ValueMeaning":{"publicId":"3028415","version":"1","preferredName":"Mucolipidosis","longName":"3028415","preferredDefinition":"A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucolipidosis","conceptCode":"C61267","definition":"A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC72-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B109-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis, NOS","valueDescription":"Mucopolysaccharidosis Not Otherwise Specified","ValueMeaning":{"publicId":"3323208","version":"1","preferredName":"Mucopolysaccharidosis Not Otherwise Specified","longName":"3323208","preferredDefinition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B138-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B151-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis","valueDescription":"Mucopolysaccharidosis","ValueMeaning":{"publicId":"3323207","version":"1","preferredName":"Mucopolysaccharidosis","longName":"3323207","preferredDefinition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3724AB2-B113-5E8E-E040-BB89AD433884","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3724AB2-B12B-5E8E-E040-BB89AD433884","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Penile","valueDescription":"Penile Neoplasm","ValueMeaning":{"publicId":"2593178","version":"1","preferredName":"Penile Neoplasm","longName":"2593178","preferredDefinition":"Cancers or tumors of the PENIS or of its component tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penile Neoplasm","conceptCode":"C3317","definition":"A benign, borderline, or malignant neoplasm that affects the penis.  Representative examples include penile hemangioma, penile intraepithelial neoplasia, and penile carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6633-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC63-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Vulvar","valueDescription":"Vulvar Neoplasm","ValueMeaning":{"publicId":"2593180","version":"1","preferredName":"Vulvar Neoplasm","longName":"2593180","preferredDefinition":"A benign or malignant neoplasm involving the vulva, i.e. the labia majora, the labia minora, and the clitoris.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vulvar Neoplasm","conceptCode":"C3443","definition":"A benign, precancerous, or malignant neoplasm that affects the vulva. Representative examples include Bartholin gland adenoma, vulvar nodular hidradenoma, vulvar intraepithelial neoplasia, vulvar carcinoma, and vulvar melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-664E-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC6D-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Cervical","valueDescription":"Cervical Neoplasm","ValueMeaning":{"publicId":"2593182","version":"1","preferredName":"Cervical Neoplasm","longName":"2593182","preferredDefinition":"Abnormal growth in the cervix, which can be benign (non cancerous) or malignant (cancerous )","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Neoplasm","conceptCode":"C2940","definition":"A benign, malignant, or precancerous neoplasm that affects the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6669-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC77-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Uterine","valueDescription":"Uterine Neoplasm","ValueMeaning":{"publicId":"2593184","version":"1","preferredName":"Uterine Neoplasm","longName":"2593184","preferredDefinition":"Abnormal growth in the tissues of uterus, either cancerous or non-cancerous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Neoplasm","conceptCode":"C3435","definition":"A benign or malignant neoplasm that affects the uterine corpus or the cervix. Representative examples of benign neoplasms include leiomyoma, adenomyoma, and endocervical polyp. Representative examples of malignant neoplasms include endometrial carcinoma, carcinosarcoma, and cervical carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6684-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC81-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Vaginal","valueDescription":"Vaginal Neoplasm","ValueMeaning":{"publicId":"2593186","version":"1","preferredName":"Vaginal Neoplasm","longName":"2593186","preferredDefinition":"Tumors or cancer of the VAGINA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Neoplasm","conceptCode":"C3437","definition":"A benign or malignant neoplasm affecting the vagina. Representative examples of benign neoplasms include squamous papilloma and melanocytic nevus. Representative examples of malignant neoplasms include carcinoma, melanoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-669F-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC8B-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2561514","version":"1","preferredName":"Melanoma","longName":"2561514","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD57-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-05","modifiedBy":"COOPERM","dateModified":"2018-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC95-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Wilms Tumor","valueDescription":"Wilms Tumor","ValueMeaning":{"publicId":"2593188","version":"1","preferredName":"Wilms Tumor","longName":"2593188","preferredDefinition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-66BA-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AC9F-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Retinoblastoma","valueDescription":"Retinoblastoma","ValueMeaning":{"publicId":"2573078","version":"1","preferredName":"Retinoblastoma","longName":"2573078","preferredDefinition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoblastoma","conceptCode":"C7541","definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA83-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ACA9-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Thymoma","valueDescription":"thymoma","ValueMeaning":{"publicId":"2579823","version":"1","preferredName":"thymoma","longName":"2579823","preferredDefinition":"A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant and probably not neoplastic. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thymoma","conceptCode":"C3411","definition":"A neoplasm arising from the epithelial cells of the thymus.  Although thymomas are usually encapsulated tumors, they may invade the capsule and infiltrate the surrounding tissues or even metastasize to distant anatomic sites.  The following morphologic subtypes are currently recognized: type A, type B, type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma.  Thymomas type B are further subdivided into types B1, B2, and B3. Thymoma type B3 usually has the most aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04DC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ACB3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Kidney / Urinary Tract","valueDescription":"Urinary System Neoplasm","ValueMeaning":{"publicId":"2593192","version":"1","preferredName":"Urinary System Neoplasm","longName":"2593192","preferredDefinition":"Tumors or cancer of the URINARY TRACT in both male and female. It does not include the male genitalia for which UROGENITAL NEOPLASMS is used for general discussions of neoplasms of both the URINARY TRACT and the GENITALIA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urinary System Neoplasm","conceptCode":"C3431","definition":"A benign or malignant, primary or metastatic neoplasm involving the urinary system (kidney, ureter, bladder, and urethra).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-66EC-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ACBD-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Ataxia Telangiectasia Syndrome","valueDescription":"Ataxia Telangiectasia Syndrome","ValueMeaning":{"publicId":"2593388","version":"1","preferredName":"Ataxia Telangiectasia Syndrome","longName":"2593388","preferredDefinition":"Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ataxia Telangiectasia Syndrome","conceptCode":"C2887","definition":"Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2883B655-AF9E-439B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD03-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"HIV Infection","valueDescription":"HIV infection","ValueMeaning":{"publicId":"2579838","version":"1","preferredName":"HIV infection","longName":"2579838v1.00","preferredDefinition":"An infection caused by the human immunodeficiency virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HIV Infection","conceptCode":"C3108","definition":"An infection caused by the human immunodeficiency virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD17-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"DiGeorge Anomaly","valueDescription":"DiGeorge Syndrome","ValueMeaning":{"publicId":"2593391","version":"1","preferredName":"DiGeorge Syndrome","longName":"2593391","preferredDefinition":"A congenital anomaly characterized by immunodeficiency, abnormal facies, congenital heart disease, hypocalcemia, and increased susceptibility to infections. Pathologic characteristics include conotruncal abnormalities and absence or hypoplasia of thymus and parathyroid glands. DiGeorge syndrome is associated with abnormalities of chromosome 22. Also known as DiGeorge anomaly. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"22q11.2 Deletion Syndrome","conceptCode":"C2989","definition":"A congenital anomaly characterized by immunodeficiency, abnormal facies, congenital heart disease, hypocalcemia, and increased susceptibility to infections. Pathologic characteristics include conotruncal abnormalities and absence or hypoplasia of thymus and parathyroid glands. DiGeorge syndrome is associated with abnormalities of chromosome 22. Also known as DiGeorge anomaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28850FD4-AA29-5B37-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD21-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Chronic Granulomatous Disease","valueDescription":"chronic granulomatous disease","ValueMeaning":{"publicId":"2579840","version":"1","preferredName":"chronic granulomatous disease","longName":"2579840","preferredDefinition":"A recessive X-linked defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Granulomatous Disease","conceptCode":"C26788","definition":"A rare genetic disorder with a predominantly X-linked recessive pattern of inheritance resulting in impaired phagocytic clearance of bacteria and fungi. It is caused by a defect in the phagocytic NADPH oxidase (phox) complex. The phagocytes can engulf pathogens but are unable to produce the microbicidal precursors needed to destroy them. Clinical signs of severe disease present in childhood with milder forms later in life. They include recurrent infection especially pneumonia, cervical lymphadenopathy and hepatosplenomegaly. The clinical course includes the appearance of granulomata in the skin and gastrointestinal or genitourinary tracts. The clinical prognosis is dependent on effectively treating and preventing infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04ED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD2B-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Common Variable Immunodeficiency","valueDescription":"Common Variable Immunodeficiency","ValueMeaning":{"publicId":"2579841","version":"1","preferredName":"Common Variable Immunodeficiency","longName":"2579841","preferredDefinition":"A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Variable Immunodeficiency","conceptCode":"C26725","definition":"A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04EE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"COOPERM","dateModified":"2020-10-16","changeDescription":"10.16.20 Updated definition to use current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD35-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Amegakaryocytosis / Congenital Thrombocytopenia","valueDescription":"Congenital Amegakaryocytosis","ValueMeaning":{"publicId":"3338481","version":"1","preferredName":"Congenital Amegakaryocytosis","longName":"3338481","preferredDefinition":"A rare disorder of infancy characterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Amegakaryocytosis","conceptCode":"C89161","definition":"A rare disorder of infancy characterized by marked reduction or absence of megakaryocytes and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0B8B-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0BA4-2D03-E040-BB89AD4355FC","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"AML or ANLL, NOS","valueDescription":"Acute Myeloid Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3322389","version":"1","preferredName":"Acute Myeloid Leukemia Not Otherwise Specified","longName":"3322389","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BC45-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0BB8-2D03-E040-BB89AD4355FC","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Chediak-Higashi Syndrome","valueDescription":"Chediak-Higashi syndrome","ValueMeaning":{"publicId":"2579849","version":"1","preferredName":"Chediak-Higashi syndrome","longName":"2579849","preferredDefinition":"A rare autosomal recessive immunodeficiency disorder characterized by abnormal intracellular protein transport. Chediak-Higashi syndrome (CHS) is characterized by immune deficiency; partial oculocutaneous albinism; a bleeding disorder due to deficient platelet dense bodies; neutropenia; neutrophils with impaired chemotaxis and bactericidal activity; recurrent infection; and abnormal natural killer (NK) cell function. CHS may be associated with hepatosplenomegaly, lymphadenopathy, anemia, thrombocytopenia, roentgenologic changes in bones, lungs and heart, and skin and psychomotor abnormalities; it is often fatal in childhood as a result of infection or an accelerated lymphoma-like phase. CHS occurs in mink, cattle, and mice, as well as man.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chediak-Higashi Syndrome","conceptCode":"C2941","definition":"A rare autosomal recessive immunodeficiency disorder characterized by abnormal intracellular protein transport. Chediak-Higashi syndrome (CHS) is characterized by immune deficiency; partial oculocutaneous albinism; a bleeding disorder due to deficient platelet dense bodies; neutropenia; neutrophils with impaired chemotaxis and bactericidal activity; recurrent infection; and abnormal natural killer (NK) cell function. CHS may be associated with hepatosplenomegaly, lymphadenopathy, anemia, thrombocytopenia, roentgenologic changes in bones, lungs and heart, and skin and psychomotor abnormalities; it is often fatal in childhood as a result of infection or an accelerated lymphoma-like phase. CHS occurs in mink, cattle, and mice, as well as man.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD67-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Wiskott-Aldrich Syndrome","valueDescription":"Wiskott-Aldrich syndrome","ValueMeaning":{"publicId":"2579850","version":"1","preferredName":"Wiskott-Aldrich syndrome","longName":"2579850","preferredDefinition":"A rare, X-linked immunodeficiency syndrome characterized by eczema, thrombocytopenia, and recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IgM levels are low and IgA and IgE levels are elevated. Lymphoreticular malignancies are common.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wiskott-Aldrich Syndrome","conceptCode":"C3448","definition":"A rare, X-linked immunodeficiency syndrome characterized by eczema, thrombocytopenia, and recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IgM levels are low and IgA and IgE levels are elevated. Lymphoreticular malignancies are common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AD71-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Chronic Lymphocytic Leukemia (CLL), NOS","valueDescription":"Chronic Lymphocytic Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"3338482","version":"1","preferredName":"Chronic Lymphocytic Leukemia Not Otherwise Specified","longName":"3338482","preferredDefinition":"The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0BC5-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0BDE-2D03-E040-BB89AD4355FC","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"CLL, T-cell","valueDescription":"T-Cell Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"3338483","version":"1","preferredName":"T-Cell Chronic Lymphocytic Leukemia","longName":"3338483","preferredDefinition":"A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood.  The T-cell is specified as the defective cell line.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Chronic Lymphocytic Leukemia","conceptCode":"C70649","definition":"A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood.  The T-cell is specified as the defective cell line.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0BEA-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0C03-2D03-E040-BB89AD4355FC","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"CML, Unknown","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Unknown","ValueMeaning":{"publicId":"3338484","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Unknown","longName":"3338484","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0C10-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0C29-2D03-E040-BB89AD4355FC","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Juvenile Idiopathic Arthritis (JIA): Systemic (Stills Disease)","valueDescription":"Still Disease","ValueMeaning":{"publicId":"3338485","version":"1","preferredName":"Still Disease","longName":"3338485","preferredDefinition":"An inflammatory disorder (a type of juvenile rheumatoid arthritis) most often affecting children. It is characterized by the presence of arthritis, salmon-colored rash, spiking fevers, fatigue, and sore throat.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Still Disease","conceptCode":"C61278","definition":"An inflammatory disorder most often affecting children. It is characterized by the presence of arthritis, salmon-colored rash, spiking fevers, fatigue, and sore throats.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0C33-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0C4C-2D03-E040-BB89AD4355FC","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Glanzmann Thrombasthenia","valueDescription":"Glanzmann Thrombasthenia","ValueMeaning":{"publicId":"2579852","version":"1","preferredName":"Glanzmann Thrombasthenia","longName":"2579852","preferredDefinition":"A rare, autosomal recessive inherited and less frequently acquired platelet disorder. It is characterized by deficient or dysfunctional glycoprotein IIb/IIIa complex. It leads to defective platelet aggregation, resulting in bleeding.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glanzmann Thrombasthenia","conceptCode":"C61249","definition":"A rare, autosomal recessive inherited and less frequently acquired platelet disorder. It is characterized by deficient or dysfunctional glycoprotein IIb/IIIa complex. It leads to defective platelet aggregation, resulting in bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ADA3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Mature B-cell (L3)","valueDescription":"Mature B-Lymphocyte","ValueMeaning":{"publicId":"3338487","version":"1","preferredName":"Mature B-Lymphocyte","longName":"3338487","preferredDefinition":"A descendant of a lymphoid stem cell that differentiates into either a plasma cell or a memory B cell in response to a specific antigen. The mature B lymphocyte develops and differentiates in the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mature B-Lymphocyte","conceptCode":"C33058","definition":"A descendant of a lymphoid stem cell that differentiates into either a plasma cell or a memory B cell in response to a specific antigen. The mature B lymphocyte develops and differentiates in the bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0C59-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0C72-2D03-E040-BB89AD4355FC","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Microscopic Polyarteritis Nodosa","valueDescription":"Microscopic Polyarteritis","ValueMeaning":{"publicId":"2757467","version":"1","preferredName":"Microscopic Polyarteritis","longName":"2757467","preferredDefinition":"A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener's granulomatosis than to classic polyarteritis nodosa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microscopic Polyarteritis","conceptCode":"C70549","definition":"A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F19E9E5-642C-39EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0C86-2D03-E040-BB89AD4355FC","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Osteopetrosis (Malignant Infantile Osteopetrosis)","valueDescription":"Osteopetrosis","ValueMeaning":{"publicId":"2593448","version":"1","preferredName":"Osteopetrosis","longName":"2593448","preferredDefinition":"Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteopetrosis","conceptCode":"C26840","definition":"A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAB4E-68BC-4B19-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ADCB-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Metachromatic Leukodystrophy (MLD)","valueDescription":"Metachromatic Leukodystrophy","ValueMeaning":{"publicId":"2593450","version":"1","preferredName":"Metachromatic Leukodystrophy","longName":"2593450","preferredDefinition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metachromatic Leukodystrophy","conceptCode":"C61251","definition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBABB0-0B0C-4B1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ADD5-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Adrenoleukodystrophy (ALD)","valueDescription":"Adrenoleukodystrophy","ValueMeaning":{"publicId":"2593452","version":"1","preferredName":"Adrenoleukodystrophy","longName":"2593452","preferredDefinition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenoleukodystrophy","conceptCode":"C61252","definition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC12-A50B-4B21-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ADDF-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Krabbe Disease (Globoid Leukodystrophy)","valueDescription":"Krabbe Disease","ValueMeaning":{"publicId":"2593454","version":"1","preferredName":"Krabbe Disease","longName":"2593454","preferredDefinition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Krabbe Disease","conceptCode":"C61254","definition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC79-C5A9-4B39-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-ADE9-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Scheie Syndrome","valueDescription":"Scheie Syndrome","ValueMeaning":{"publicId":"2582069","version":"1","preferredName":"Scheie Syndrome","longName":"2582069","preferredDefinition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scheie Syndrome","conceptCode":"C61265","definition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0DA2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AE2F-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Morquio (IV)","valueDescription":"Morquio Syndrome","ValueMeaning":{"publicId":"2593471","version":"1","preferredName":"Morquio Syndrome","longName":"2593471","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morquio Syndrome","conceptCode":"C61263","definition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBEE5A-A52B-56E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AE4D-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Other Arthritis","valueDescription":"Arthritis Other","ValueMeaning":{"publicId":"3326300","version":"1","preferredName":"Arthritis Other","longName":"3326300","preferredDefinition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arthritis","conceptCode":"C2883","definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B10C-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B125-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Glycogen Storage Disease","valueDescription":"Glycogen Storage Disease","ValueMeaning":{"publicId":"2593481","version":"1","preferredName":"Glycogen Storage Disease","longName":"2593481","preferredDefinition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease","conceptCode":"C61272","definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BD3AD6-BCD6-64E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AE93-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Other AML","valueDescription":"Acute Myeloid Leukemia Other","ValueMeaning":{"publicId":"3326299","version":"1","preferredName":"Acute Myeloid Leukemia Other","longName":"3326299","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B0E6-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B0FF-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Autoimmune Disease","valueDescription":"Autoimmune Disease Other","ValueMeaning":{"publicId":"3326301","version":"1","preferredName":"Autoimmune Disease Other","longName":"3326301","preferredDefinition":"A condition in which the body recognizes its own tissues as foreign and directs an immune response against them.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Disease","conceptCode":"C2889","definition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B132-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B14B-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other B-Cell Lymphoma","valueDescription":"Diffuse Large B-Cell Lymphoma Other","ValueMeaning":{"publicId":"3326302","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Other","longName":"3326302","preferredDefinition":"This non-Hodgkin's lymphoma is characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin's lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, T-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large B-cell lymphoma with expression of full-length ALK. (WHO, 2001) -- 2003: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B158-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B171-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Connective Tissue Disease","valueDescription":"Connective Tissue Disorder Other","ValueMeaning":{"publicId":"3326303","version":"1","preferredName":"Connective Tissue Disorder Other","longName":"3326303","preferredDefinition":"A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Connective Tissue Disorder","conceptCode":"C26729","definition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B17E-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B197-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Hemoglobinopathy","valueDescription":"Hemoglobinopathy Other","ValueMeaning":{"publicId":"3326304","version":"1","preferredName":"Hemoglobinopathy Other","longName":"3326304","preferredDefinition":"An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemoglobinopathy","conceptCode":"C3092","definition":"An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B1A4-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B1BD-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Hodgkin Lymphoma","valueDescription":"Hodgkin Lymphoma Other","ValueMeaning":{"publicId":"3326305","version":"1","preferredName":"Hodgkin Lymphoma Other","longName":"3326305","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes. Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B1CA-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B1E3-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Inherited Metabolic Disorder","valueDescription":"Congenital Metabolic Disorder Other","ValueMeaning":{"publicId":"3326306","version":"1","preferredName":"Congenital Metabolic Disorder Other","longName":"3326306","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B1F0-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B209-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Langerhans Cell Histiocytosis (Histiocytosis-X)","valueDescription":"Langerhans Cell Histiocytosis","ValueMeaning":{"publicId":"2559022","version":"1","preferredName":"Langerhans Cell Histiocytosis","longName":"2559022","preferredDefinition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination.  Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease.  The clinical course is generally related to the number of organs affected at presentation.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Histiocytosis","conceptCode":"C3107","definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B39B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AF01-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hemophagocytosis","valueDescription":"hemophagocytosis","ValueMeaning":{"publicId":"2579881","version":"1","preferredName":"hemophagocytosis","longName":"2579881","preferredDefinition":"The term hemophagocytosis describes the pathologic finding of activated macrophages, engulfing erythrocytes, leukocytes, platelets, and their precursor cells. (from Medscape: Hemophagocytic Syndromes and Infection)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophagocytosis","conceptCode":"C35985","definition":"The term hemophagocytosis describes the pathologic finding of activated macrophages, engulfing erythrocytes, leukocytes, platelets, and their precursor cells. (from Medscape: Hemophagocytic Syndromes and Infection)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0516-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AF0B-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Other Inherited Platelet Abnormality","valueDescription":"Congenital Platelets Abnormality Other","ValueMeaning":{"publicId":"3326307","version":"1","preferredName":"Congenital Platelets Abnormality Other","longName":"3326307","preferredDefinition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Platelets Abnormality","conceptCode":"C61247","definition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B216-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B22F-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other JIA","valueDescription":"Still Disease Other","ValueMeaning":{"publicId":"3326308","version":"1","preferredName":"Still Disease Other","longName":"3326308","preferredDefinition":"An inflammatory disorder (a type of juvenile rheumatoid arthritis) most often affecting children. It is characterized by the presence of arthritis, salmon-colored rash, spiking fevers, fatigue, and sore throat.\r\n: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Still Disease","conceptCode":"C61278","definition":"An inflammatory disorder most often affecting children. It is characterized by the presence of arthritis, salmon-colored rash, spiking fevers, fatigue, and sore throats.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B23C-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B255-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Rheumatoid Arthritis","valueDescription":"Rheumatoid Arthritis","ValueMeaning":{"publicId":"2570667","version":"1","preferredName":"Rheumatoid Arthritis","longName":"2570667","preferredDefinition":"A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rheumatoid Arthritis","conceptCode":"C2884","definition":"A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E118-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CZECHS","dateModified":"2008-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AF47-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Multiple Sclerosis","valueDescription":"multiple sclerosis","ValueMeaning":{"publicId":"2579888","version":"1","preferredName":"multiple sclerosis","longName":"2579888","preferredDefinition":"A disorder of the central nervous system marked by weakness, numbness, a loss of muscle coordination, and problems with vision, speech, and bladder control. Multiple sclerosis is thought to be an autoimmune disease in which the body's immune system destroys myelin. Myelin is a substance that contains both protein and fat (lipid), serving as a nerve insulator and helping in the transmission of nerve signals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Sclerosis","conceptCode":"C3243","definition":"A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-051D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AF79-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Multiple Myeloma, NOS","valueDescription":"Plasma Cell Myeloma Not Otherwise Specified","ValueMeaning":{"publicId":"3323717","version":"1","preferredName":"Plasma Cell Myeloma Not Otherwise Specified","longName":"3323717","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8245-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-825E-6627-E040-BB89AD4359F7","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Multiple Myeloma/ Plasma Cell Disorder (PCD)","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-8272-6627-E040-BB89AD4359F7","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Myasthenia Gravis","valueDescription":"Myasthenia Gravis","ValueMeaning":{"publicId":"3143924","version":"1","preferredName":"Myasthenia Gravis","longName":"3143924","preferredDefinition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness.  It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myasthenia Gravis","conceptCode":"C60989","definition":"A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9167B9F7-3DD6-C748-E040-BB89AD432898","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-827C-6627-E040-BB89AD4359F7","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Mycosis Fungoides and Sezary Syndrome","valueDescription":"Mycosis Fungoides and Sezary Syndrome","ValueMeaning":{"publicId":"2593091","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome","longName":"2593091","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome","conceptCode":"C9265","definition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8FA4-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-8286-6627-E040-BB89AD4359F7","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Myelofibrosis with Myeloid Metaplasia","valueDescription":"Primary Myelofibrosis","ValueMeaning":{"publicId":"3323718","version":"1","preferredName":"Primary Myelofibrosis","longName":"3323718","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8290-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-82A9-6627-E040-BB89AD4359F7","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Necrotizing Arteritis","valueDescription":"Necrotizing Arteritis","ValueMeaning":{"publicId":"3323719","version":"1","preferredName":"Necrotizing Arteritis","longName":"3323719","preferredDefinition":"An arteritis characterized by the presence of inflammation and necrosis in the arterial wall.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Necrotizing Arteritis","conceptCode":"C61281","definition":"An arteritis characterized by the presence of inflammation and necrosis in the arterial wall.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-82B3-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-82CB-6627-E040-BB89AD4359F7","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Neuronal Ceroid Lipofuscinosis","valueDescription":"Neuronal Ceroid Lipofuscinosis","ValueMeaning":{"publicId":"3211301","version":"1","preferredName":"Neuronal Ceroid Lipofuscinosis","longName":"3211301","preferredDefinition":"A group of mostly autosomal recessive inherited neurodegenerative disorders characterized by accumulation of lipofuscin in the neuronal cells and in other tissues including liver, spleen, kidneys, and myocardium. Signs and symptoms include motor disturbances and cognitive decline.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuronal Ceroid Lipofuscinosis","conceptCode":"C61257","definition":"A group of mostly autosomal recessive inherited neurodegenerative disorders characterized by accumulation of lipofuscin in the neuronal cells and in other tissues including liver, spleen, kidneys, and myocardium. Signs and symptoms include motor disturbances and cognitive decline.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EAB7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-82D5-6627-E040-BB89AD4359F7","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Neutrophil Actin Defect","valueDescription":"Neutrophil Actin Defect","ValueMeaning":{"publicId":"3323720","version":"1","preferredName":"Neutrophil Actin Defect","longName":"3323720","preferredDefinition":"A genetic disorder characterized by defective polymorphonuclear cell actin function, resulting in impaired granulocyte motility.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neutrophil Actin Defect","conceptCode":"C61243","definition":"A genetic disorder characterized by defective polymorphonuclear cell actin function, resulting in impaired granulocyte motility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-82DF-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-82F7-6627-E040-BB89AD4359F7","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Niemann-Pick Disease","valueDescription":"Niemann-Pick Disease","ValueMeaning":{"publicId":"3028411","version":"1","preferredName":"Niemann-Pick Disease","longName":"3028411","preferredDefinition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niemann-Pick Disease","conceptCode":"C61269","definition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FBBC-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-8301-6627-E040-BB89AD4359F7","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Nodal Marginal Zone B-cell Lymphoma (+/- Monocytoid B-cells)","valueDescription":"Nodal Marginal Zone B-Cell Lymphoma","ValueMeaning":{"publicId":"2838642","version":"1","preferredName":"Nodal Marginal Zone B-Cell Lymphoma","longName":"2838642","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5AB3-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-8315-6627-E040-BB89AD4359F7","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Non-Hodgkin's Lymphoma, NOS","valueDescription":"Non-Hodgkin Lymphoma Not Otherwise Specified","ValueMeaning":{"publicId":"3323721","version":"1","preferredName":"Non-Hodgkin Lymphoma Not Otherwise Specified","longName":"3323721","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8322-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-833B-6627-E040-BB89AD4359F7","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Omenn Syndrome","valueDescription":"Omenn Syndrome","ValueMeaning":{"publicId":"3323722","version":"1","preferredName":"Omenn Syndrome","longName":"3323722","preferredDefinition":"An autosomal recessive combined immunodeficiency syndrome caused by mutations in the RAG-1 and RAG-2 genes. It is characterized by the presence of alopecia, erythroderma, desquamation, lymphadenopathy, and chronic diarrhea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omenn Syndrome","conceptCode":"C61240","definition":"An autosomal recessive combined immunodeficiency syndrome caused by mutations in the RAG-1 and RAG-2 genes. It is characterized by the presence of alopecia, erythroderma, desquamation, lymphadenopathy, and chronic diarrhea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8345-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-835E-6627-E040-BB89AD4359F7","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Acute Leukemia","valueDescription":"Acute Leukemia Other","ValueMeaning":{"publicId":"3323723","version":"1","preferredName":"Acute Leukemia Other","longName":"3323723","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood. The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts). According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL).: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-836B-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-8384-6627-E040-BB89AD4359F7","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other ALL","valueDescription":"Acute Lymphoblastic Leukemia Other","ValueMeaning":{"publicId":"3323724","version":"1","preferredName":"Acute Lymphoblastic Leukemia Other","longName":"3323724","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8391-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B381BEF5-83AA-6627-E040-BB89AD4359F7","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Leukemia","valueDescription":"Leukemia Other","ValueMeaning":{"publicId":"3326309","version":"1","preferredName":"Leukemia Other","longName":"3326309","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B262-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B27B-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other MDS","valueDescription":"Myelodysplastic Syndrome Other","ValueMeaning":{"publicId":"3326310","version":"1","preferredName":"Myelodysplastic Syndrome Other","longName":"3326310","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B288-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B2A1-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Mucopolysaccharidosis","valueDescription":"Mucopolysaccharidosis Other","ValueMeaning":{"publicId":"3326311","version":"1","preferredName":"Mucopolysaccharidosis Other","longName":"3326311","preferredDefinition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B2AE-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B2C7-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Sjogren Syndrome","valueDescription":"Sjogren's Syndrome","ValueMeaning":{"publicId":"2593564","version":"1","preferredName":"Sjogren's Syndrome","longName":"2593564","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sjogren Syndrome","conceptCode":"C26883","definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED297-469F-6CF9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AFB5-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Other SCID","valueDescription":"Severe Combined Immunodeficiency Other","ValueMeaning":{"publicId":"3326313","version":"1","preferredName":"Severe Combined Immunodeficiency Other","longName":"3326313","preferredDefinition":"X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Combined Immunodeficiency","conceptCode":"C3472","definition":"X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B2FA-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B313-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Antiphospholipid Syndrome","valueDescription":"antiphospholipid syndrome","ValueMeaning":{"publicId":"2579893","version":"1","preferredName":"antiphospholipid syndrome","longName":"2579893","preferredDefinition":" A syndrome associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses, marked by the presence of antibodies directed against phospholipids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiphospholipid Syndrome","conceptCode":"C61283","definition":"A disorder caused by the presence of autoantibodies directed against phospholipids, causing a hypercoaguable state, which may result in blood clots, stroke, heart attack, and in women, significant pregnancy-related complications, including miscarriage and still birth. The syndrome is often associated with other autoimmune disorders, most commonly lupus erythematosus, and infections, including syphilis and Lyme disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0522-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AFC9-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2569497","version":"1","preferredName":"Vasculitis","longName":"2569497","preferredDefinition":"Inflammation of a blood vessel.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"CZECHS","dateModified":"2008-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AFD3-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Wegener Granulomatosis","valueDescription":"Wegener's Granulomatosis","ValueMeaning":{"publicId":"2593570","version":"1","preferredName":"Wegener's Granulomatosis","longName":"2593570","preferredDefinition":"A multisystem disease chiefly affecting males, characterized by necrotizing granulomatous vasculitis involving the upper and lower respiratory tracts, glomerulonephritis, and variable degrees of systemic, small vessel vasculitis, which is generally considered to represent an aberrant hypersensitivity reaction to an unknown antigen. (Dorland, 27th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulomatosis with Polyangiitis","conceptCode":"C3444","definition":"A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01AFF-5E3F-08FB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AFDD-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Churg-Strauss","valueDescription":"Churg-Strauss Syndrome","ValueMeaning":{"publicId":"2593573","version":"1","preferredName":"Churg-Strauss Syndrome","longName":"2593573","preferredDefinition":"Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eosinophilic Granulomatosis with Polyangiitis","conceptCode":"C34481","definition":"An autoimmune necrotizing vasculitis with the formation of granulomas. It is a pulmonary and systemic vasculitis associated with eosinophilia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01BC7-F115-0924-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AFF1-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Giant Cell Arteritis","valueDescription":"Temporal Arteritis","ValueMeaning":{"publicId":"2593575","version":"1","preferredName":"Temporal Arteritis","longName":"2593575","preferredDefinition":"A systemic autoimmune vasculitis occurring primarily in people over the age of 50. Pathologic features include a necrotizing panarteritis including granulomas and giant cells. There is a predilection for involvement of central nervous system blood vessels and the most frequent neurologic complication is an OPTIC NEUROPATHY, ISCHEMIC. Large blood vessels may become involved, including the aorta. Clinical manifestations may include myalgias, weight loss, headache, visual loss, necrosis of the skin or tongue, and chest discomfort. Superficial scalp arteries may become tender and enlarged. A related condition, juvenile temporal arteritis, tends to occur in the first or second decade of life. (From Adams et al., Principles of Neurology, 6th ed, p856)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temporal Arteritis","conceptCode":"C35065","definition":"An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01C2C-F0F2-0929-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-AFFB-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Takayasu","valueDescription":"Takayasu's Arteritis","ValueMeaning":{"publicId":"2593577","version":"1","preferredName":"Takayasu's Arteritis","longName":"2593577","preferredDefinition":"A thrombo-obliterative process of the great vessels stemming from the aortic arch, occurring generally in young women. Radial and carotid pulses are typically obliterated. Skin changes are due to the disturbed circulation. There may be loss of hair and atrophy of the skin and its appendages with underlying muscle atrophy. (Andrews' Diseases of the Skin, 8th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Takayasu Arteritis","conceptCode":"C35062","definition":"A large vessel vasculitis affecting the aorta and its branches. It usually affects young females. It causes vascular obstruction, resulting in asymmetric pulses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01C94-A173-0932-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B005-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Behcet Syndrome","valueDescription":"Behcet Syndrome","ValueMeaning":{"publicId":"2593579","version":"1","preferredName":"Behcet Syndrome","longName":"2593579","preferredDefinition":"Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS, THROMBOPHLEBITIS, gastrointestinal ulcerations, RETINAL VASCULITIS, and OPTIC ATROPHY may occur as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Behcet Syndrome","conceptCode":"C34416","definition":"A rare chronic inflammatory disorder of unknown etiology. It is characterized by the development of ulcers in the mouth and genital region and uveitis. Other signs and symptoms include arthritis, deep vein thrombosis and superficial thrombophlebitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01CF8-E883-093C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B00F-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Other Solid Tumor","valueDescription":"Solid Neoplasm Other","ValueMeaning":{"publicId":"3326314","version":"1","preferredName":"Solid Neoplasm Other","longName":"3326314","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B320-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B339-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other T-Cell/NK-Cell Lymphoma","valueDescription":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Other","ValueMeaning":{"publicId":"3326315","version":"1","preferredName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Other","longName":"3326315","preferredDefinition":"A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","conceptCode":"C3468","definition":"This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B346-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B35F-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Vasculitis","valueDescription":"Vasculitis Other","ValueMeaning":{"publicId":"3326316","version":"1","preferredName":"Vasculitis Other","longName":"3326316","preferredDefinition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener's granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B36C-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B385-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Idiopathic Thrombocytopenic Purpura (ITP)","valueDescription":"Idiopathic Thrombocytopenic Purpura","ValueMeaning":{"publicId":"2579903","version":"1","preferredName":"Idiopathic Thrombocytopenic Purpura","longName":"2579903","preferredDefinition":"Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Immune Thrombocytopenia","conceptCode":"C3446","definition":"Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-052C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B037-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Hemolytic Anemia","valueDescription":"Hemolytic Anemia","ValueMeaning":{"publicId":"2579904","version":"1","preferredName":"Hemolytic Anemia","longName":"2579904","preferredDefinition":"Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemolytic Anemia","conceptCode":"C34376","definition":"Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-052D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B041-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Ovarian","valueDescription":"Ovarian Carcinoma","ValueMeaning":{"publicId":"2593147","version":"1","preferredName":"Ovarian Carcinoma","longName":"2593147","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E43-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B38F-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Overlap Necrotizing arteritis","valueDescription":"Overlap Necrotizing Arteritis","ValueMeaning":{"publicId":"3326317","version":"1","preferredName":"Overlap Necrotizing Arteritis","longName":"3326317","preferredDefinition":"A necrotizing arteritis that exhibits characteristic features of several distinct vascular disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overlap Necrotizing Arteritis","conceptCode":"C61282","definition":"A necrotizing arteritis that exhibits characteristic features of several distinct vascular disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B399-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B3B2-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Crohn Disease","valueDescription":"Crohn Disease","ValueMeaning":{"publicId":"2577525","version":"1","preferredName":"Crohn Disease","longName":"2577525","preferredDefinition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn's disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crohn Disease","conceptCode":"C2965","definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B05F-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Ulcerative Colitis","valueDescription":"Ulcerative Colitis","ValueMeaning":{"publicId":"2577524","version":"1","preferredName":"Ulcerative Colitis","longName":"2577524","preferredDefinition":"Inflammatory disease of unknown cause which involves the mucosa of the colon. Onset may be acute and fulminant, and its course often continues chronically in an intermittent or continuous form. Diarrhea is a common symptom and bleeding an almost constant concomitant symptom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ulcerative Colitis","conceptCode":"C2952","definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CZECHS","dateModified":"2008-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B069-9DF5-E040-BB89AD4316B4","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"PCD, NOS","valueDescription":"Plasma Cell Neoplasm Not Otherwise Specified","ValueMeaning":{"publicId":"3326318","version":"1","preferredName":"Plasma Cell Neoplasm Not Otherwise Specified","longName":"3326318","preferredDefinition":"An unusual leukemia characterized by the presence of clonal (malignant) plasma cells in the peripheral blood.  The plasma cells infiltrate the spleen, liver, bone marrow, and lymph nodes. The total number of leukocytes in the peripheral blood may range from normal levels to 80,000 or 90,000 per cu mm, and 5% to 90% may be plasma cells.  Although there are clinicopathologic differences between plasma cell leukemia and plasma cell myeloma, they may be phases of the same malignant process. -- 2003: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Neoplasm","conceptCode":"C4665","definition":"A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes multiple myeloma, plasma cell leukemia, plasmacytoma, and plasma cell post-transplant lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B3BF-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B3D8-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Peripheral T-cell Lymphoma, NOS","valueDescription":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Not Otherwise Specified","ValueMeaning":{"publicId":"3326319","version":"1","preferredName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Not Otherwise Specified","longName":"3326319","preferredDefinition":"A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","conceptCode":"C3468","definition":"This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B3E5-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B3FE-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1 unknown; BCR/ABL unknown","valueDescription":"Ph Unknown/BCR Unknown","ValueMeaning":{"publicId":"3326320","version":"1","preferredName":"Ph Unknown/BCR Unknown","longName":"3326320","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not tested; therefore it is not known whether it is present or not. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph Unknown/BCR Unknown","conceptCode":"C70628","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not tested; therefore it is not known whether it is present or not.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B40A-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B423-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Monoclonal gammopathy of unknown significance (MGUS)","valueDescription":"Monoclonal Gammopathy of Undetermined Significance","ValueMeaning":{"publicId":"2838621","version":"1","preferredName":"Monoclonal Gammopathy of Undetermined Significance","longName":"2838621","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Undetermined Significance","conceptCode":"C3996","definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0A2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B36C94EE-B0B9-9DF5-E040-BB89AD4316B4","beginDate":"2009-09-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","deletedIndicator":"No"},{"value":"Ph1 unknown; BCR/ABL+","valueDescription":"Ph Unknown/BCR+","ValueMeaning":{"publicId":"2688784","version":"1","preferredName":"Ph Unknown/BCR+","longName":"2688784","preferredDefinition":"Philadelphia chromosome abnormality; (9;22)(q34;q11) was not tested; therefore it is not known if it was present or not; bcr/abl gene rearrangement was found. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph Unknown/BCR+","conceptCode":"C70623","definition":"Philadelphia chromosome abnormality; (9;22)(q34;q11) was not tested; therefore it is not known if it was present or not; bcr/abl gene rearrangement was found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ACDB1-D5A7-1BF2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B42D-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1 unknown; BCR/ABL-","valueDescription":"Ph Unknown/BCR-","ValueMeaning":{"publicId":"3326321","version":"1","preferredName":"Ph Unknown/BCR-","longName":"3326321","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not found. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph Unknown/BCR-","conceptCode":"C70627","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B439-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B452-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1+; BCR/ABL unknown","valueDescription":"Ph+/BCR Unknown","ValueMeaning":{"publicId":"2688785","version":"1","preferredName":"Ph+/BCR Unknown","longName":"2688785","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph+/BCR Unknown","conceptCode":"C70624","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ACDB1-D5CE-1BF2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B45C-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1+; BCR/ABL+","valueDescription":"Ph+/BCR+","ValueMeaning":{"publicId":"3326322","version":"1","preferredName":"Ph+/BCR+","longName":"3326322","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was found.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph+/BCR+","conceptCode":"C79095","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B468-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B480-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1-; BCR/ABL unknown","valueDescription":"Ph-/BCR Unknown","ValueMeaning":{"publicId":"3326323","version":"1","preferredName":"Ph-/BCR Unknown","longName":"3326323","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph-/BCR Unknown","conceptCode":"C70630","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B48C-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B4A5-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1-; BCR/ABL+","valueDescription":"Ph-/BCR+","ValueMeaning":{"publicId":"2688786","version":"1","preferredName":"Ph-/BCR+","longName":"2688786","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was found. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph-/BCR+","conceptCode":"C70602","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ACDB1-D5F5-1BF2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B4AF-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Ph1-; BCR/ABL-","valueDescription":"Ph -/BCR-ABL-","ValueMeaning":{"publicId":"3326324","version":"1","preferredName":"Ph -/BCR-ABL-","longName":"3326324","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not found. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph -/BCR-ABL-","conceptCode":"C70629","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B4BB-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B4D4-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"PLL, B-cell","valueDescription":"B-Cell Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2837830","version":"1","preferredName":"B-Cell Prolymphocytic Leukemia","longName":"2837830","preferredDefinition":"A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Cell Prolymphocytic Leukemia","conceptCode":"C4753","definition":"A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-47FB-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B4E8-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"PLL, T-cell","valueDescription":"T-Cell Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2838858","version":"1","preferredName":"T-Cell Prolymphocytic Leukemia","longName":"2838858","preferredDefinition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Prolymphocytic Leukemia","conceptCode":"C4752","definition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A5F-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B4FC-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Polymyositis / Dermatomyositis","valueDescription":"Polymyositis And/Or Dermatomyositis","ValueMeaning":{"publicId":"3326325","version":"1","preferredName":"Polymyositis And/Or Dermatomyositis","longName":"3326325","preferredDefinition":"An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.: Used to indicate that either or both of two items or options may be valid.: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyositis","conceptCode":"C26925","definition":"An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dermatomyositis","conceptCode":"C26744","definition":"Inflammation of the skin and muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B50A-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B523-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Precursor B-lymphoblastic Lymphoma / Leukemia","valueDescription":"Precursor B-Lymphoblastic Lymphoma/Leukemia","ValueMeaning":{"publicId":"2593075","version":"1","preferredName":"Precursor B-Lymphoblastic Lymphoma/Leukemia","longName":"2593075","preferredDefinition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called precursor B lymphoblastic leukemia (B-cell acute lymphoblastic leukemia).  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8936","definition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-19BC-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B537-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Precursor T-Lymphoblastic Lymphoma/Leukemia","valueDescription":"precursor T-lymphoblastic lymphoma/leukemia","ValueMeaning":{"publicId":"2568286","version":"1","preferredName":"Precursor T-lymphoblastic lymphoma/leukemia","longName":"2568286v1.00","preferredDefinition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8694","definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B541-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Prolymphocytic Leukemia","valueDescription":"Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2590867","version":"1","preferredName":"Prolymphocytic Leukemia","longName":"2590867","preferredDefinition":"PLL. A type of chronic lymphocyctic leukemia (CLL), in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolymphocytic Leukemia","conceptCode":"C3181","definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2843C971-29F3-37A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B54D-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Prostate Neoplasm","valueDescription":"Prostate Neoplasm","ValueMeaning":{"publicId":"2593176","version":"1","preferredName":"Prostate Neoplasm","longName":"2593176","preferredDefinition":"A benign or malignant tumor involving the prostate gland. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Neoplasm","conceptCode":"C3343","definition":"A benign, borderline, or malignant neoplasm that affects the prostate gland.  Representative examples include benign prostate phyllodes tumor, prostatic intraepithelial neoplasia, prostate carcinoma, and prostate sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6618-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B557-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Psoriatic Arthritis / Psoriasis","valueDescription":"Psoriasis And/Or Psoriatic Arthritis","ValueMeaning":{"publicId":"3326326","version":"1","preferredName":"Psoriasis And/Or Psoriatic Arthritis","longName":"3326326","preferredDefinition":"A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. Psoriatic lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region; the pathology involves an accelerated epidermopoiesis. Psoriasis is associated with increased risk for melanoma, squamous cell carcinoma, and basal cell carcinoma.: Used to indicate that either or both of two items or options may be valid.: Joint inflammation associated with psoriasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoriasis","conceptCode":"C3346","definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Psoriatic Arthritis","conceptCode":"C61277","definition":"Joint inflammation associated with psoriasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B565-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B57E-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Refractory Anemia","valueDescription":"Refractory Anemia","ValueMeaning":{"publicId":"2771856","version":"1","preferredName":"Refractory Anemia","longName":"2771856","preferredDefinition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Anemia","conceptCode":"C2872","definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF1D-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B588-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Refractory Anemia with Excess Blasts","valueDescription":"Refractory Anemia with Excess Blasts","ValueMeaning":{"publicId":"2838712","version":"1","preferredName":"Myelodysplastic Syndrome with Excess Blasts","longName":"2838712v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C7506","definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9753-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B59E-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Refractory Anemia with Ringed Sideroblasts","valueDescription":"Refractory Anemia with Ringed Sideroblasts","ValueMeaning":{"publicId":"2771857","version":"1","preferredName":"Refractory Anemia with Ringed Sideroblasts","longName":"2771857","preferredDefinition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.  It occurs primarily in older individuals.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts","conceptCode":"C4036","definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF42-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B5A8-375A-E040-BB89AD436460","beginDate":"2007-01-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Reticular Dysgenesis","valueDescription":"Reticular Dysgenesis","ValueMeaning":{"publicId":"3326327","version":"1","preferredName":"Reticular Dysgenesis","longName":"3326327","preferredDefinition":"A rare severe combined immunodeficiency disorder characterized by congenital agranulocytosis, lymphoid tissue and thymic tissue hypoplasia, and lymphopenia. Both cellular and humoral immunities are absent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reticular Dysgenesis","conceptCode":"C27070","definition":"A rare severe combined immunodeficiency disorder characterized by congenital agranulocytosis, lymphoid tissue and thymic tissue hypoplasia, and lymphopenia. Both cellular and humoral immunities are absent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B5B2-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B5CB-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Sanfilippo","valueDescription":"Sanfilippo Syndrome","ValueMeaning":{"publicId":"3326328","version":"1","preferredName":"Sanfilippo Syndrome","longName":"3326328","preferredDefinition":"A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides.  Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sanfilippo Syndrome","conceptCode":"C61262","definition":"A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides. Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B5D5-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B5ED-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Sarcoma, NOS","valueDescription":"Sarcoma Not Otherwise Specified","ValueMeaning":{"publicId":"3326329","version":"1","preferredName":"Sarcoma Not Otherwise Specified","longName":"3326329","preferredDefinition":"A usually aggressive malignant mesenchymal cell tumor most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.  Sarcomas occur in both children and adults.  The prognosis depends largely on the degree of differentiation (grade) of the tumor.  Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. -- 2004: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B5FA-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B613-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Schwachmann-Diamond Syndrome","valueDescription":"Schwachmann-Diamond Syndrome","ValueMeaning":{"publicId":"3326330","version":"1","preferredName":"Schwachmann-Diamond Syndrome","longName":"3326330","preferredDefinition":"A rare, autosomal recessive disorder characterized by exocrine pancreas insufficiency, skeletal abnormalities, bone marrow dysfunction, and an increased incidence of leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Shwachman-Diamond Syndrome","conceptCode":"C61235","definition":"A rare, autosomal recessive disorder characterized by exocrine pancreas insufficiency, skeletal abnormalities, bone marrow dysfunction, and an increased incidence of leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B61D-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B635-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"SCID, NOS","valueDescription":"Severe Combined Immunodeficiency Not Otherwise Specified","ValueMeaning":{"publicId":"3326331","version":"1","preferredName":"Severe Combined Immunodeficiency Not Otherwise Specified","longName":"3326331","preferredDefinition":"X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Combined Immunodeficiency","conceptCode":"C3472","definition":"X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B642-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B65B-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Severe Aplastic Anemia","valueDescription":"Severe Aplastic Anemia","ValueMeaning":{"publicId":"3326332","version":"1","preferredName":"Severe Aplastic Anemia","longName":"3326332","preferredDefinition":"Life-threatening anemia associated with a high risk of infection or bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Aplastic Anemia","conceptCode":"C61229","definition":"Life-threatening anemia associated with a high risk of infection or bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B665-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B67E-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Sickle Thalassemia","valueDescription":"Sickle Cell-Thalassemia","ValueMeaning":{"publicId":"3326333","version":"1","preferredName":"Sickle Cell-Thalassemia","longName":"3326333","preferredDefinition":"Hemolytic anemia, in which patients are heterozygous for both the sickle cell gene and a thalassemia gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sickle Cell-Thalassemia","conceptCode":"C61237","definition":"Hemolytic anemia, in which patients are heterozygous for both the sickle cell gene and a thalassemia gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B688-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B6A0-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Soft Tissue Sarcoma","valueDescription":"Soft Tissue Sarcoma","ValueMeaning":{"publicId":"2593160","version":"1","preferredName":"Soft Tissue Sarcoma","longName":"2593160","preferredDefinition":"(TISH-oo sar-KO-ma) A sarcoma that begins in the muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Sarcoma","conceptCode":"C9306","definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6F77-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B6AC-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Solid Tumor, NOS","valueDescription":"Solid Neoplasm Not Otherwise Specified","ValueMeaning":{"publicId":"3326334","version":"1","preferredName":"Solid Neoplasm Not Otherwise Specified","longName":"3326334","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B6B9-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B6D4-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Systemic Lupus Erythematosis","valueDescription":"Systemic Lupus Erythematosus","ValueMeaning":{"publicId":"2593562","version":"1","preferredName":"Systemic Lupus Erythematosus","longName":"2593562","preferredDefinition":"A chronic inflammatory connective tissue disease marked by skin rashes, joint pain and swelling, inflammation of the kidneys, inflammation of the fibrous tissue surrounding the heart (i.e., the pericardium), as well as other problems.  Not all affected individuals display all of these problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Lupus Erythematosus","conceptCode":"C3201","definition":"An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED21B-19CD-6CE2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B6E8-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Scleroderma","valueDescription":"Scleroderma","ValueMeaning":{"publicId":"2593560","version":"1","preferredName":"Scleroderma","longName":"2593560","preferredDefinition":"A chronic disorder marked by hardening and thickening of the skin.  Scleroderma can be localized or it can affect the entire body (systemic).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scleroderma","conceptCode":"C26746","definition":"A localized or systemic chronic and progressive autoimmune disorder characterized by thickening of the skin and the connective tissues. Localized scleroderma affects only the skin. Systemic scleroderma affects internal organs, including the heart, lungs, gastrointestinal tract, and kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED1B6-B07C-6CBF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B6F4-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Testicular","valueDescription":"Testicular Germ Cell Tumor","ValueMeaning":{"publicId":"3326335","version":"1","preferredName":"Testicular Germ Cell Tumor","longName":"3326335","preferredDefinition":"A germ cell tumor arising from the testis.  Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testicular Germ Cell Tumor","conceptCode":"C8591","definition":"A germ cell tumor arising from the testis. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B6FE-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B716-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Waldenstrom Macroglobulinemia","valueDescription":"Waldenstrom Macroglobulinemia","ValueMeaning":{"publicId":"3040402","version":"1","preferredName":"Waldenstrom Macroglobulinemia","longName":"3040402","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"832F1E62-11E1-273F-E040-BB89AD432C6A","latestVersionIndicator":"Yes","beginDate":"2010-04-01","endDate":null,"createdBy":"ALEYR","dateCreated":"2010-04-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B720-375A-E040-BB89AD436460","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Wolman Disease","valueDescription":"Wolman Disease","ValueMeaning":{"publicId":"3028409","version":"1","preferredName":"Wolman Disease","longName":"3028409","preferredDefinition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolman Disease","conceptCode":"C61271","definition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FAFB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B72A-375A-E040-BB89AD436460","beginDate":"2007-02-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"X-Linked Lymphoproliferative Syndrome","valueDescription":"X-Linked Lymphoproliferative Syndrome","ValueMeaning":{"publicId":"3326336","version":"1","preferredName":"X-Linked Lymphoproliferative Syndrome","longName":"3326336","preferredDefinition":"An X-linked immunodeficiency syndrome that exclusivesly affects males, although females can be carriers. The syndrome is characterized by life-threatening episodes of infectious mononucleosis, hypogammaglobulinemia, and subsequent development of lymphomas (usually B-cell lymphomas) and other lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"X-Linked Lymphoproliferative Syndrome","conceptCode":"C61246","definition":"An X-linked immunodeficiency syndrome that exclusively affects males, although females can be carriers. It is caused by mutation(s) in SH2D1A and/or XIAP genes and is characterized by life-threatening episodes of infectious mononucleosis, hypogammaglobulinemia, and subsequent development of lymphomas (usually B-cell lymphomas) and other lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B734-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B74D-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"X-Linked Severe Combined Immunodeficiency","valueDescription":"X-Linked Severe Combined Immunodeficiency","ValueMeaning":{"publicId":"2593406","version":"1","preferredName":"X-Linked Severe Combined Immunodeficiency","longName":"2593406","preferredDefinition":"Rare congenital disorder inherited as an X-linked defect characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"X-Linked Severe Combined Immunodeficiency","conceptCode":"C4682","definition":"Rare congenital disorder inherited as an X-linked defect characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28856182-985A-6F60-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3862B52-B757-375A-E040-BB89AD436460","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","deletedIndicator":"No"},{"value":"Other Constitutional Anemia","valueDescription":"Fanconi Anemia Other","ValueMeaning":{"publicId":"3338488","version":"1","preferredName":"Fanconi Anemia Other","longName":"3338488","preferredDefinition":"A rare and often fatal inherited disease in which the bone marrow fails to produce red blood cells, white blood cells, platelets, or a combination of these cells. The disease may transform into myelodysplastic syndrome or leukemia.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0C93-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4B1E777-0CAC-2D03-E040-BB89AD4355FC","beginDate":"2007-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","deletedIndicator":"No"},{"value":"Breast Cancer, NOS","valueDescription":"Breast Carcinoma Not Otherwise Specified","ValueMeaning":{"publicId":"3590101","version":"1","preferredName":"Breast Carcinoma Not Otherwise Specified","longName":"3590101","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.: Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA116DCD-3603-3F6C-E040-BB89AD430A5B","latestVersionIndicator":"Yes","beginDate":"2012-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA116DCD-361B-3F6C-E040-BB89AD430A5B","beginDate":"2007-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-19","modifiedBy":"ONEDATA","dateModified":"2012-09-19","deletedIndicator":"No"},{"value":"Lymphoplasmacytic lymphoma","valueDescription":"Lymphoplasmacytic Lymphoma","ValueMeaning":{"publicId":"2629954","version":"1","preferredName":"Lymphoplasmacytic Lymphoma","longName":"2629954","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E665ACD-9834-52CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-18","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-04-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Added NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6A8531F-A613-A4E9-E040-BB89AD43785B","beginDate":"2013-02-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-02-26","modifiedBy":"ONEDATA","dateModified":"2013-02-26","deletedIndicator":"No"},{"value":"Other disease","valueDescription":"Other Disease or Disorder","ValueMeaning":{"publicId":"3158622","version":"1","preferredName":"Other Disease or Disorder","longName":"3158622","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94B8AE1D-5BF8-C169-E040-BB89AD435EB4","latestVersionIndicator":"Yes","beginDate":"2010-11-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E57C0FD5-C47D-7335-E040-BB89AD43178E","beginDate":"2013-09-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-09-03","modifiedBy":"ONEDATA","dateModified":"2013-09-03","deletedIndicator":"No"},{"value":"Lymphoma","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"2567355","version":"1","preferredName":"Lymphoma","longName":"2567355","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D428-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-78F8-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2943908","version":"1","preferredName":"Vasculitis","longName":"2943908","preferredDefinition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener's granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742B257F-AAE1-95B9-E040-BB89AD4354AE","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-78CC-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"Psoriasis","valueDescription":"Psoriasis","ValueMeaning":{"publicId":"4276834","version":"1","preferredName":"Psoriasis","longName":"4276834","preferredDefinition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoriasis","conceptCode":"C3346","definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7A209D6-78D6-98DB-E040-BB89AD4339B1","latestVersionIndicator":"Yes","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-78EE-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"Lymphoproliferative disorder","valueDescription":"Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3235573","version":"1","preferredName":"Lymphoproliferative Disorder","longName":"3235573","preferredDefinition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A366F43E-37D9-9973-E040-BB89AD43108C","latestVersionIndicator":"Yes","beginDate":"2011-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-7902-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"Hypogammaglobulinemia","valueDescription":"Hypogammaglobulinemia","ValueMeaning":{"publicId":"4276835","version":"1","preferredName":"Hypogammaglobulinemia","longName":"4276835","preferredDefinition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypogammaglobulinemia","conceptCode":"C26931","definition":"A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7A209D6-790C-98DB-E040-BB89AD4339B1","latestVersionIndicator":"Yes","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-7925-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"Colitis","valueDescription":"Colitis","ValueMeaning":{"publicId":"2684803","version":"1","preferredName":"Colitis","longName":"2684803","preferredDefinition":"Inflammation of the colon.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colitis","conceptCode":"C26723","definition":"Inflammation of the colon.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B0AABC6-5698-5AC2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-09-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-792F-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"Aplastic anemia","valueDescription":"Aplastic Anemia","ValueMeaning":{"publicId":"2593270","version":"1","preferredName":"Aplastic Anemia","longName":"2593270","preferredDefinition":"A condition in which the bone marrow is unable to produce blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aplastic Anemia","conceptCode":"C2870","definition":"Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880D74E-659D-0A0D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7A209D6-7939-98DB-E040-BB89AD4339B1","beginDate":"2014-04-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-22","modifiedBy":"ONEDATA","dateModified":"2014-04-22","deletedIndicator":"No"},{"value":"EBV infection without HLH","valueDescription":"Negation Evidence Hemophagocytic Lymphohistiocytosis Concurrent With Epstein-Barr Virus Infectious Disorder","ValueMeaning":{"publicId":"4280191","version":"1","preferredName":"Negation Evidence Hemophagocytic Lymphohistiocytosis Concurrent With Epstein-Barr Virus Infectious Disorder","longName":"4280191","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Knowledge on which to base belief.: A rare but potentially life-threatening disorder characterized by the proliferation of histiocytes and macrophages and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary, due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.: Occurring or operating at the same time.: Used to indicate the presence of something or someone.: A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt's lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations.: A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Evidence","conceptCode":"C43583","definition":"Knowledge on which to base belief.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Hemophagocytic Lymphohistiocytosis","conceptCode":"C34792","definition":"A rare, but potentially life-threatening disorder, characterized by the proliferation of histiocytes and macrophages, and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Concurrent","conceptCode":"C25456","definition":"Occurring or operating at the same time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Epstein-Barr Virus","conceptCode":"C14204","definition":"A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt's lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B65AF7-D302-63D1-E040-BB89AD43367F","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B65AF7-D31B-63D1-E040-BB89AD43367F","beginDate":"2014-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"},{"value":"Epstein-Barr Virus (EBV) infection with evidence of Hemophagocytic Lymphohistiocytosis (HLH)","valueDescription":"Evidence Hemophagocytic Lymphohistiocytosis Concurrent With Epstein-Barr Virus Infectious Disorder","ValueMeaning":{"publicId":"4280192","version":"1","preferredName":"Evidence Hemophagocytic Lymphohistiocytosis Concurrent With Epstein-Barr Virus Infectious Disorder","longName":"4280192","preferredDefinition":"Knowledge on which to base belief.: A rare but potentially life-threatening disorder characterized by the proliferation of histiocytes and macrophages and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary, due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.: Occurring or operating at the same time.: Used to indicate the presence of something or someone.: A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt's lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations.: A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Evidence","conceptCode":"C43583","definition":"Knowledge on which to base belief.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Hemophagocytic Lymphohistiocytosis","conceptCode":"C34792","definition":"A rare, but potentially life-threatening disorder, characterized by the proliferation of histiocytes and macrophages, and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Concurrent","conceptCode":"C25456","definition":"Occurring or operating at the same time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Epstein-Barr Virus","conceptCode":"C14204","definition":"A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt's lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B65AF7-D32C-63D1-E040-BB89AD43367F","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7B65AF7-D345-63D1-E040-BB89AD43367F","beginDate":"2014-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-04-23","modifiedBy":"ONEDATA","dateModified":"2014-04-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3322357","version":"1","preferredName":"Disease or Disorder Present Name","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Being or existing in a specified place or at the specified time.:The words or language units by which a thing is known.","longName":"C2991:C25626:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36C6763-0BD9-E38C-E040-BB89AD434A4C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36C94EE-A63F-9DF5-E040-BB89AD4316B4","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"KUMMEROA","dateModified":"2020-12-16","changeDescription":". 2020-12-16 ak Ok to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964888","version":"1","longName":"2016r1: Myeloma Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:value ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"MACpre_assess_diag_mac_dis_name","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What type of disease was pres","type":"Preferred Question Text","description":"What type of disease was present?","url":null,"context":"NHLBI"},{"name":"Specify the disease diagnosis:","type":"Alternate Question Text","description":"Specify the disease diagnosis:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2946347","type":"BRIDG Mapping Path","description":"PerformedDiagnosis [first] > AssessedResultRelationship > PerformedObservation > PerformedDiagnosis.value [second] WHERE PerformedDiagnosis.value [first] = \"Multiple Myeloma\"","url":null,"context":"NHLBI"},{"name":"What is the diagnosis?","type":"Alternate Question Text","description":"What is the diagnosis?","url":null,"context":"NHLBI"},{"name":"Specify if the following disorders were present","type":"Alternate Question Text","description":"Specify if the following disorders were present","url":null,"context":"NHLBI"},{"name":"Specify if the recipient displayed evidence of the following disorders","type":"Alternate Question Text","description":"Specify if the recipient displayed evidence of the following disorders","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"746D32D6-F79D-1467-E040-BB89AD436E21","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-09-25","modifiedBy":"KUMMEROA","dateModified":"2020-12-16","changeDescription":". 2020-12-16 ak OK to release per WZ. System generated def displayed as alt def. AK 11/17/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}